TEKCAPITAL Annual Report 2021

FY2021 Annual Report · TEKCAPITAL

Loading PDF…

2021
Annual Report & Accounts

R I S K F A C T O R S A N D F O R W A R D - L O O K I N G S T A T E M E N T S

This Report is directed only at Relevant Persons and must not be acted on or relied upon by
persons who are not Relevant Persons. Any other person who receives this Report should not rely
or act upon it. By accepting this Report the recipient is deemed to represent and warrant that: (i)
they are a person who falls within the above description of persons entitled to receive the Report;
(ii) they have read, agree and will comply with the contents of this notice. The securities mentioned
herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended
(the “Securities Act”), or under any U.S. State securities laws, and may not be offered or sold in the
United States of America or its territories or possessions (the “United States”) unless they are
registered under the Securities Act or pursuant to an exemption from or in a transaction not subject
to the registration requirements of the Securities Act. This Report is not being made available to
persons in Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or any
other jurisdiction in which it may be unlawful to do so, and it should not be delivered or distributed,
directly or indirectly, into or within any such jurisdictions.

taxation,

the legal,

rely on their own examination of

Investors must
financial and other
consequences of an investment in the Company, including the merits of investing and the risks
involved. Prospective investors should not treat the contents of this Report as advice relating to
legal, taxation or investment matters and are advised to consult their own professional advisers
concerning any acquisition of shares in the Company. Certain information contained in this Report
has been obtained from published sources prepared by other parties. Certain other information has
been extracted from unpublished sources prepared by other parties which have been made
available to the Company. The Company has not carried out an independent investigation to verify
the accuracy and completeness of such third-party information. No responsibility is accepted by the
Company or any of its directors, officers, employees or agents for the accuracy or completeness of
such information.

All statements of opinion and/or belief contained in this Report and all views expressed represent
the directors’ own current assessment and interpretation of information available to them as at the
date of this Report. In addition, this Report contains certain “forward-looking statements”, including
but not limited to, the statements regarding the Company’s overall objectives and strategic plans,
timetables and capital expenditures. Forward-looking statements express, as at the date of this
Report, the Company’s plans, estimates, valuations, forecasts, projections, opinions, expectations
or beliefs as to future events, results or performance. Forward-looking statements involve a number
of risks and uncertainties, many of which are beyond the Company’s control, and there can be no
assurance that such statements will prove to be accurate. No assurance is given that such forward-
looking statements or views are correct or that the objectives of the Company will be achieved.
Further, valuations of
the Company’s portfolio investments and net asset value can and will
fluctuate over time due to a wide variety of factors both company-specific and macroeconomic.
the
Changes in net asset values can have a significant impact on revenue and earnings of
Company and its future prospects.

R I S K F A C T O R S A N D F O R W A R D - L O O K I N G S T A T E M E N T S

Additionally, the current Coronavirus pandemic may produce negative economic activities
which could reduce the company’s economic performance and the performance of its portfolio
companies in ways that are difficult to quantify at this juncture. It may cause a downturn in the
markets in which the Company operates, reduce the Company’s net asset values, revenue,
cash flow, access to investment capital and other factors which could negatively impact the
Company. As a result, the reader is cautioned not to place reliance on these statements or
views and no responsibility is accepted by the Company or any of its directors, officers,
employees or agents in respect thereof. The Company does not undertake to update any
forward-looking statement or other information that is contained in this Report. Neither the
Company nor any of its shareholders, directors, officers, agents, employees or advisers take
any responsibility for, or will accept any liability whether direct or indirect, express or implied,
contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the
information contained in this Report or for any of the opinions contained herein, or for any
errors, omissions or misstatements or for any loss, howsoever arising, from the use of this
Report. Neither the issue of this Report nor any part of its contents is to be taken as any form
of contract, commitment or recommendation on the part of the Company or the directors of the
Company. In no circumstances will the Company be responsible for any costs, losses or
expenses incurred in connection with any appraisal, analysis or investigation of the Company.
This Report should not be considered a recommendation by the Company or any of
its
affiliates in relation to any prospective acquisition or disposition of shares in the Company. No
undertaking, Report, warranty or other assurance, express or implied, is made or given by or
on behalf of the Company or any of its affiliates, any of its directors, officers or employees or
any other person as to the accuracy, completeness or fairness of the information or opinions
contained in this Report and no responsibility or liability is accepted for any such information or
opinions or for any errors or omissions.

Intellectual Property Risk Factors
Tekcapital plc’s mission is to create valuable products from university intellectual property that
can improve people’s lives. Therefore, our ability to compete in the market may be negatively
affected if our portfolio companies lose some or all of their intellectual property rights, if patent
rights that they rely on are invalidated, or if they are unable to obtain other intellectual property
rights. Our success will depend on the ability of our portfolio companies to obtain and protect
their trade secrets, and for them to
patents on their technology and products, to protect
maintain their rights to licensed intellectual property or technologies. Their patent applications
or those of our licensors may not result in the issue of patents in the United States or other
countries. Their patents or those of their licensors may not afford meaningful protection for our
technology and products. Others may challenge their patents or those of their licensors by
proceedings such as interference, oppositions and re-examinations or in litigation seeking to
establish the invalidity of their patents. In the event that one or more of their patents are
challenged, a court may invalidate the patent(s) or determine that
the patent(s) is not
enforceable, which could harm their competitive position and ours. If one or more of our
portfolio company patents are invalidated or found to be unenforceable, or if the scope of the
claims in any of these patents is limited by a court decision, our portfolio companies could lose
certain market exclusivity afforded by patents owned or in-licensed by us, and potential
competitors could more easily bring products to the market that directly compete with our own.

R I S K F A C T O R S A N D F O R W A R D - L O O K I N G S T A T E M E N T S

The uncertainties and costs surrounding the prosecution of their patent applications and the
cost of enforcement or defence of their issued patents could have a material adverse effect on
our business and financial condition. To protect or enforce their patent rights, our portfolio
companies may initiate interference proceedings, oppositions, re-examinations or litigation
against others. However,
time and divert
in these
management’s attention from other business concerns. They may not prevail
activities. If they are not successful in these activities, the prevailing party may obtain superior
rights to our claimed inventions and technology, which could adversely affect the ability of our
portfolio companies to successfully market and commercialize their products and services.
Claims by other companies may infringe the intellectual property rights on which our portfolio
companies rely, and if such rights are deemed to be invalid it could adversely affect our
portfolio companies and ourselves as investors in these companies.

these activities are expensive,

take significant

issues and inherent uncertainties in intellectual property litigation.

From time to time, companies may assert, patent, copyright and other intellectual proprietary
rights against our portfolio company’s products or technologies. These claims can result e in
lawsuits being brought against our portfolio companies or their holding company in the future.
They and we may not prevail in any lawsuits alleging patent infringement, given the complex
If any of our
technical
portfolio company products, technologies or activities, from which our portfolio companies
derive or expect to derive a substantial portion of their revenues and were found to infringe on
another company’s intellectual property rights, they could be subject to an injunction that would
force the removal of such product from the market or they could be required to redesign such
product, which could be costly. They could also be ordered to pay damages or other
compensation, including punitive damages and attorneys’ fees to such other company. A
negative outcome in any such litigation could also severely disrupt the sales of their marketed
products to their customers which in turn could harm their relationships with their customers,
their market share and their product revenues. Even if
in
defending any intellectual property litigation, such litigation is expensive and time-consuming to
address, will divert our management’s attention from their business and may harm their
reputation and ours.

they are ultimately successful

Several of our portfolio companies may be subject to complex and costly regulation and if
government regulations are interpreted or enforced in a manner adverse to them, they may be
subject to enforcement actions, penalties, exclusion, and other material
limitations on their
operations and this may have a negative impact on their financial performance.

All of the risks can have a material, negative affect on our net asset value, revenue,
performance and the success of our business and the portfolio companies we invested
in.

C ONTENTS

PAGE

STRATEGIC REPORT

6
7
8
13
14
15
20
26
27

28
31

34
41
42
43
44
45
78
79
80

Overview
Investment Case
Key Highlights
Q&A with Executive Chairman
Tekcapital at a Glance
Portfolio Review
Chairman’s Summary
Financial Review & Key Performance Indicators
Board of Directors

DIRECTORS' REPORT

Directors’ Report
Corporate Governance

OUR FINANCIALS

Independent auditor’s report
Consolidated Statement of Comprehensive Income
Consolidated Statement of Financial Position
Consolidated Statement of Changes in Equity
Consolidated Statement of Cash Flows
Notes to the Financial Statements
Company Statement of Financial Position
Company Statement of Changes in Equity
Notes to Company Financial Statements

T E K C A P I T A L TRANSFORMS UNIVERSITY DISCOVERIES
INTO VALUABLE PRODUCTS

We find and invest
university network, that we believe can enhance people’s lives.

in exciting new discoveries from our global

We also provide services to universities and companies to help them
analyse and commercialise their innovations. Using these services,
we have built a compelling group of portfolio companies to
commercialise the high value properties we have uncovered.

Value of investment portfolio (US$m)

$62.5

$13.7

$20.1

$30.5

2018

2019

2020

2021

We believe that when you couple commercialisation ready, strong
university IP with star power management, vibrant companies can
emerge.

When we realise exits, the Group’s goal is to distribute a portion of
the proceeds as a special dividend to our shareholders.

INVESTMENT C A S E & F I N A N C I A L
P E R F O R M A N C E

A C C E S S T O O N E O F T H E
W O R L D ’ S L A R G E S T
N E TW O R K S O F UNIVERSITY IP
4,500+ UNIVERSITIES

Net Assets
U$68.1m

Compound Annual Growth
Rate (CAGR) of Net Assets
over the past five years
45%

Return on Assets (ROA)
54%

Return on invested capital
(ROIC)
42%

Total Income
including fair value gains
$29.2m

Profit after tax
$26.4m

TECHNOLOGY REVIEW
CAPABILITY

~60 SCIENCE ADVISORS

NUMBER O F INDUSTRY
L E A D E R S RECRUITED B Y
P O R T F O L I O C O M P A NIES

15 INDUSTRY LEADERS

NUMBER O F P O R T FO L I O
C O M P A I N I E S FA C I N G $1B+
MARKETS
4 PORTFOLIO COMPANIES

K E Y HIGHLIGHTS

FINANCIAL
Our investment objective is to achieve long-term growth of net assets and returns on invested capital
through the commercialisation of university discoveries that can make a positive impact on people’s lives. In
2021 we met this objective. It was the most productive year for value creation in the Group’s history:

 Net Assets increased 108% to US$68.0m, a record

level (2020: US$32.7m)

o NAV per share increased 37% to US$0.48

(2020: $0.35)

 Portfolio valuation increased 105% to US$62.5m

(2020:US$30.4m)

 Total income US$29.2m (2020: US$9.9m), primarily

driven by the net increase of US$28.1m
(unrealised) in fair value of portfolio companies
(2020: US$8.7m)

 Profit after tax: US$26.4m (2020: U S $7.7m)

 Share placings totaling US$9.4m completed

during the period (2020: US$2.6m)

Net Assets (US$m)

68.1

32.7

22.5

16.1

10.7

2017

2018

2019

2020

2021

INVESTMENT PORTFOLIO

Salarius Ltd manufactures Microsalt®, a new, patented, all natural, non-GMO,
Kosher, low-sodium salt that tastes great and has approximately half of the
sodium of regular table salt.

Salarius Ltd 97.2%
ownership

www.salarius.co

Investment Rationale:
The snack food industry is focused on developing and providing better-for-you products that both taste
good and help reduce sodium intake. The reason for this is that excess sodium consumption
contributes to cardiovascular disease, a leading cause of premature death globally. To help address this
problem, Salarius has developed a patented process for producing micron sized salt crystals.
Microsalt® has all the flavour of salt with roughly half the sodium for topical applications such as
crisps, pretzels, nuts, popcorn and other salty snacks.

Recent developments:

•

Expanded sales of its SaltMe® full flavor, low sodium chips brand in 2,200 Kroger, stores. Kroger is
the largest supermarket chain in the U.S. We believe this is the first national roll-out of full-flavour,
low-sodium potato chips in the U.S.
In addition to Kroger, SaltMe! crisps are now available at
approximately 200 other retail purchase points.

•

Awarded the most innovative sodium reduction food technology provider in 2021 by GHP Magazine.

• Winner of the Star Entrepreneur Award as the #1 start-up led by a P&G Alumni.

• Completed its Crowdfund successfully raising $750,000 in December 2021.

K E Y HIGHLIGHTS

Lucyd® Limited (“Lucyd”) is seeking to Upgrade Your Eyewear® by
developing and selling designer smart eyewear at affordable prices. Lucyd®
is seeking to Upgrade Your Eyewear® by developing and selling designer
smart eyewear at affordable prices. Innovative Eyewear, Inc., its ~80% owned
U.S. operating subsidiary, was the first company to deliver prescription
glasses with Bluetooth® technology in 2019. Their frames help you stay
connected safely and conveniently, by enabling many common smartphone
tasks to be performed handsfree via voice assistants

Lucyd Ltd
100% ownership

www.lucyd.co

Investment Rationale:
In the U.S. pedestrian fatalities have increased by 60% from 2009 to 2019¹. Open ear audio found in Lucyd
smart glasses can help pedestrians maintain situational awareness whist walking running and cycling.
Approximately 2/3rds of
adult population need corrective lenses, and advancements in Bluetooth
technology have enabled it to be incorporated into traditional eyeglass form factors. This combination created
a new type of eyewear with built-in speakers, microphones and touch controls. Lucyd smart eyewear allows
the wearer to forego headphones and use their glasses to listen to audio content and talk to others. Since the
speakers are open-ear, Lucyd e-glasses enables the wearer to stay connected to their digital
life while
maintaining situational and social awareness.

the

Recent developments:
•

Innovative Eyewear Launched Lucyd® Lyte® in January 2021. Their smart sunglass and prescription
eyewear is the perfect complement for active lifestyles. As of the date of this report Lucyd Lytes have
received more than 600 5-star ratings on Amazon and Lucyd.co websites.

• Announced multiple new hires, including Frank Rescigna, Head of Global Sales, Ken Strominger, Director

of Sports & Electronics Sales and Alex Rivera, Manager of Graphics and Photography.

• Signed a distribution agreement with D. Landstrom Associates,

to build distribution of Lucyd Lyte™

•

Bluetooth® smart-glasses in big box retail stores in the U.S.
It expanded its ecommerce sales channels with retail sales. Starting with none in June 2021, onboarded
more than 200 retail stores as of the date of this report.

• Appointed Olivia "Dibby" Bartlett as a non-executive director. Dibby has served more than 30 years in the
industry and is currently president of the Opticians Association of America. Appointed Kristen
optical
McLaughlin to its board as a non-executive director. Kristen has a distinguished career in the optical
industry where she has served as director of marketing for Silhouette International and brand manager for
Daniel Swarovski Crystal Eyewear.

• Submitted a draft registration statement with the U.S. Securities and Exchange Commission (the "SEC"),

for a proposed initial public offering ("IPO") of shares of its common stock in the United States.

Guident Ltd
100% ownership

www.guident.co

is developing remote monitoring and
Guident Limited (“Guident”)
control software to improve safety of autonomous vehicles and land-
based delivery devices. Guident’s software will
incorporate artificial
intelligence and advanced network technologies to minimize signal
latency and improve the safety of autonomous vehicles.

Investment Rationale:
Vehicles of all types are rapidly becoming electric and autonomous. Whilst Autonomous Vehicles (“AVs”)
are projected to be significantly safer than traditional vehicles, there will still be mishaps and in many
instances there will be no vehicle operator present to help resolve these problems. We believe remote
human interaction will be needed to address these mishaps. Guident’s remote monitoring and control
centre will monitor vehicles and if necessary provide additional support such as calling first responders,
taking over control of the vehicle to move it out of harm’s way and providing real-time communication with
passengers and pedestrians. Over time, we believe remote monitoring centres will be required in most
jurisdictions where AV’s operate.

S O U R C E
¹ https://www.caranddriver.com/news/a31136893/pedestrian-deaths-increase-2019/

K E Y HIGHLIGHTS

Recent developments:
•

the company defined its go to market strategy, engaged advisors with relevant

Demonstrated its low-latency (~38msec), vehicle control software to power its Remote Monitoring
and Control Centre (RMCC). This is expected to be used in their first RMCC for AVs,
to be
launched later this year in Boca Raton, Florida. The RMCC will be able to monitor multiple vehicles
from a remote, secure monitoring centre, akin to air traffic control for ground-based vehicles.
During 2021,
industry experience and entered discussions with numerous prospective customers.
the company announced the successful demonstration of
technology in Boca Raton, Florida.
During 2021,
the company has also progressed the engineering development of
regenerative shock absorbers and completed their fabrication. Testing of the shocks are on-going.
Multiple large OEM’s have expressed an interest
absorbers as a tool for potential EV range extension.

in evaluating Guident’s regenerative shock

its remote monitoring and control

its prototype

Belluscura plc (“Belluscura”) is a respiratory medical device company that has
developed and launched an improved portable oxygen concentrator (POC) to
provide on-the-go supplemental O2. The company believes its product is the
first FDA cleared, modular POC with a user-replaceable filter cartridge.
Belluscura aims to make POC’s more affordable to those who need them.

Belluscura plc
~15% ownership

www.belluscura.com

Investment Rationale:
Worldwide, approximately 300m individuals suffer from COPD (chronic obstructive pulmonary disease).
Many of these patients require supplemental oxygen. As there is no cure for COPD, over time patients
require greater amounts of oxygen, and if they use a portable oxygen concentrator, this means they must
often replace their devices with greater capacity models as their disease progresses. With Belluscura’s
the filter cartridges to enable higher capacity oxygen flow
new patented device, users can swap out
without having to buy a new device, like upgrading memory on a laptop. The result is more affordable
oxygen therapy which increases the number of people who can avail themselves of these life-extending
and life saving devices.

Recent Developments:
•
•

Belluscura received FDA clearance in March 2021.
In April 2021, Tekcapital converted its warrants and options held in Belluscura at an average
exercise price of 21 pence for new ordinary shares in Belluscura, bringing total shares held to 17.1
million.
On May 28, 2021, Belluscura consummated its IPO at 45 pence per share and commenced trading
on the AIM Market of the London Stock Exchange.
Post IPO, the Company continued to rapidly expand its sales and distribution capabilities in the US
and development of its new products.
On Nov 4, 2021 Belluscura announced that demand for its X-PLO2R™ portable oxygen concentrators
significantly exceeded expectations.
On Nov 29, 2021 Belluscura announced it has received reimbursement approval from U.S. Centers
for Medicare & Medicaid Services, further expanding the potential market for these devices.
As of 30 November 2021 Belluscura shares traded at 99 pence per share, valuing Tekcapital’s
holding at $22.7m compared to $2m as of 30 November 2020.

•

K E Y HIGHLIGHTS

C O R P O R A T E

As part of our continuing efforts to develop our team and expand our services:
•

Tekcapital developed and delivered a successful webinar series "The Impact of Nanotechnology" to
participants from the technology and innovation ecosystem in Latin America.

•

Tekcapital was invited to participate at the 2021 Red TTO (Technology Transfer Offices) Mexico Event.
The annual congress is where the innovation ecosystem of Mexico converges.
Tekcapital participated as a sponsor and exhibitor at the 2021 Eastern, Central and Canadian Region
Meetings hosted by the Association of University Technology Managers.
In 2021, Tekcapital delivered more than 250 Invention Evaluator reports to universities worldwide, to
help them assess the market potential of their new technologies and has added corporate clients
including Hewlett Packard Enterprises, to its client roster. Additionally, the Vortechs Group, Tekcapital’s
executive search firm, won 15 executive search assignments in 2021.

Dr. Clifford Gross, Executive Chairman said:
“We are glad to report very strong full-year performance for the Group, with net
assets increasing by 108% to US$68.1m, a record level. Our key portfolio
companies are progressing well and should reach significant additional
milestones by the end of 2022. We are also pleased to highlight Belluscura’s
successful IPO during the period, Lucyd’s subsidiary Innovative Eyewear, Inc.’s
IPO with a listing on the
filing of
NASDAQ,
the roll-out of Microsalt’s SaltMe! Crisps in Kroger supermarkets
throughout the U.S., and Guident’s demonstration of their remote monitoring and
control center with industry leading low glass-to-glass latency. We are excited
about what our portfolio companies have achieved in 2021 and their prospects for
2022.”

its registration statement

for a potential

K E Y HIGHLIGHTS

POST PERIOD END PORTFOLIO COMPANY HIGHLIGHTS

Belluscura



Executed an agreement with InnoMax Medical Technology to manufacture its X-PLO2R® portable
oxygen concentrator in China, which is expected to more than double its manufacturing capacity whilst
accelerating its international expansion. Nearly 100 million people in China have chronic obstructive
pulmonary disease ("COPD"). This is 400% larger than the U.S. COPD population.

Awarded a Distribution and Pricing Agreement ("DAPA") from the United States Defense Logistics
Agency ("DLA") for the X-PLOR. The United States government is the largest buyer in the world.

Announced that its sales in January and February of 2022 exceeded forecasts and surpassed 2021
total.

Salarius & Microsalt Inc, its US subsidiary:



In Q1 2022 SaltMe!® Chips have seen a 40-fold increase in sales compared to Q1 2021.

Appointed Dan Emery as a non-executive member of its board of directors. Dan has more than 25
years of experience in the food industry, including 15 years as vice president of sales and marketing at
Pilgrim's Pride, during which time sales grew from US$970 million to US$8.5 billion, with a balance
between retail and food service.

Appointed Rick Guiney as CEO. Rick has more than 35 years of experience in the food industry,
including 30+ years as President & CEO of Classic Snacks, Inc., where he pioneered the ground-up
development of the business and transformed it into a market-leading direct distribution company in the
food industry. Classic Snacks was included on the Inc. 500 Fastest Growing Company List, and quickly
became a nationwide snack food packager and distributor to airlines, restaurants, hotels, country clubs,
bars, taverns, and retail private label customers.

Lucyd & Innovative Eyewear Inc, its US subsidiary:



Announced it has filed a registration statement and is seeking to raise $10m in an IPO to be traded on
the NASDAQ under the ticker: LUCY, which it seeks to consummate as soon as practicable given
current market conditions.

Launched the Vyrb app, a voice social medial program designed for Lucyd Lyte smart glasses and other
hearables, for IOS and Android.

Announced it has been approved by DICK's Sporting Goods® to provide its Lucyd Lyte® smart eyewear
on dickssportinggoods.com and by BestBuy.ca to place its products on Best Buy's Canadian
ecommerce site.

Guident & Guident Corp, its US subsidiary:



Has been selected as a vendor by JTA’s Procurement Review Committee for JTA Proposal No. P-22-
010 entitled “JTA Test Environment” to provide remote monitoring and control services for three years.

Announced it is working with Airspan Networks NYSE American: MIMO) to provide customers with
connectivity and software solutions for autonomous vehicles for smart city applications, using CBRS
(Citizens Broadband Radio Service) spectrum.

Announced that it filed their 8th patent application covering improvements to its remote monitoring and
control centre for AVs. The U.S. patent application #17/579,203 is entitled: "Near Real-Time Data and
Video Streaming System for a Vehicle, Robot or Drone".

Announced that their Regenerative Shock Absorber prototypes have been fabricated and are being
evaluated by independent
is
currently in discussions with potential customers and strategic partners to potentially manufacture and
use their RSA's.

facilities to confirm their performance and capabilities. Guident

test

“WE BELIEVE 2022 WILL BE A BREAKTHROUGH YEAR
FOR OUR PORTFOLIO COMPANIES”

DR CLIFFORD M. GROSS
EXECUTIVE CHAIRMAN

Q & A WI TH O U R E X E C U T I V E CHAI RM AN

 What are the most important milestones reached by Tekcapital and its portfolio companies in

2022?

 Belluscura received FDA clearance for its portable oxygen concentrator and subsequently completed a
raising approximately $25m on the LSE’s AIM market. Additionally, Belluscura
its unique, proprietary oxygen

successful
onboarded five distributors and began manufacturing and selling of
concentrator.

IPO,

 Salarius received a large order for its SaltMe crisps for national supermarket distribution in Kroger, the
largest supermarket in the U.S.. Shipments of their chips are expected to total several million dollars in
2022, marking the first time a low-sodium, full flavor snack will be available for customers nationwide.
Salaius’ Microsalt subsidiary raised $750,000 in an oversubscribed crowdfund.

 Guident successfully demonstrated its remote monitoring and control centre in Boca Raton, Florida,
with amongst the lowest latency for any such monitoring system. Additionally, Guident successfully
designed and manufactured their first-generation regenerative shock absorbers.

 Lucyd’s portfolio company Innovative eyewear filed a registration statement for an IPO and a potential
listing on the NASDAQ. Additionally, Innovative Eyewear launched more than a dozen new styles of
smart eyewear,
including the world’s first titanium front-framed smart glasses, and launched retail
distribution into 200 optical stores in addition to expanding its ecommerce distribution on Amazon,
BestBuy.com and its in-house website lucyd.co. Lucyd also completed two crowdfunds, the first raising
$1m in an oversubscribed offering and the second raising ~$150k in a top-up round at a $20m pre-
money valuation.

 What milestones do es the Group hope to accomplish in 2022?
 A successful flotation of Innovative Eyewear, Inc.
 Significant sales expansion of Microsalt and its SaltMe crisps.
 Venture funding of Guident Corp. and the on-boarding of its first commercial customer.
 The successful testing of Guident’s regenerative shock absorbers.

 What is the Company’s plan once monetization of a significant exit happens for most or all of

the portfolio companies?
We will continue to expand our portfolio with additional high value investments.

T E K C A P I T A L AT A GLANCE

Tekcapital has built one of the largest university IP networks in the world, to help it find and

review market-ready technologies. The Group provides universities and corporate clients

with a range of technology transfer services while simultaneously identifying compelling

technologies for its own portfolio, for subsequent commercialisation. We believe this unique

combination provides a competitive advantage in the sector, as we both use and sell our IP

investment services. This keeps us close to our technology suppliers and allows the

company to have a vibrant pipeline of technologies at low cost.

TEKCAPITAL’S FORMULA OF COUPLING MARKET-READY IP WITH TALENTED
MANAGEMENT, HELPS POSITION THE GROUP FOR LONG-TERM GROWTH, AND
INCREASES THE PROBABILITY OF MEANINGFUL EXITS

Value of investment portfolio (US$m)

2018

2019

2020

2021

$62.5

$30.5

$13.7

$20.1

WE HAVE VISABILITY TO UNIVERSITY-DEVELOPED IP FROM 4,500+ RESEARCH

INSTITUTIONS ACROSS 160 COUNTRIES

P O R T F O L I O R E V I E W

PAT E NT E D LOW-SODI UM SALT

The snack food industry is focused on developing and providing
taste great and reduce sodium intake.
better-for-you products that
The reason for this is that excess sodium consumption contributes to
cardiovascular disease, a leading cause of premature death globally.
To address this problem, Salarius has developed a patented process
for producing micron-sized salt crystals that provide all of the flavor of
salt with roughly half of the sodium for topical food applications.

Salarius has developed what we believe to be the world’s
smallest edible salt crystals with its patented Microsalt®. With
Microsalt®, companies can make full flavour snacks with the
same saltiness as traditional snacks yet with half of the sodium.

Microsalt® uses micron-sized sodium chloride crystals that dissolve
faster, is all natural, non-GMO, Kosher and doesn’t contain any of the
additives found in other sodium reduction products.

The global Sodium Reduction Ingredients Market is expected to reach
US$1.62 billion by 2024 with a CAGR of 7.3% from 2019 to 2024¹.
Salty snack market was worth US$26b in 2019 alone. Recently,
Salarius has secured two food brokers and the leading U.S. natural
food distributor for its product in the United States and Mexico.

Cardiovascular disease is the world’s leading health problem causing
17.9 million pre-mature deaths annually and is related to high sodium
consumption, especially in snacks and other prepared foods.
According to the U.S. FDA, reducing daily sodium intake from 3,400
reduce approximately 28,000–50,000
mg to 2,300 mg/day will
premature deaths per year in the U.S..

During 2021, the company made significant progress in expanding its
sales of its SaltMe® full flavor, low sodium snack brand in more than
2,400 retail establishments, including the largest supermarket chain in
the U.S..

Tekcapital ownership of
Salarius Ltd

97.15%

TOTAL ADDRESSABLE
MARKET

$1.1B²

$1.1B

CAGR

11.15% ²

S O U R C E
¹ https://www.futuremarketinsights.com/reports/sodium-reduction-ingredient-market
²https://www.marketdataforecast.com/market-reports/sodium-reduction-ingredients-
market

P O R T F O L I O R E V I E W

LUCYD: T HE C L E A R C HO I C E F O R T E C H E Y E WE A R

Lucyd is seeking to Upgrade Your Eyewear® by producing
designer eyewear with smart
features at affordable prices.
Lucyd was the first company to deliver prescription glasses
with Bluetooth® technology in 2019. Their frames help you
stay connected safely and conveniently.

With Lucyd frames, you can stay focused on the world while
listening to music and using voice assistants.
making calls,

Sitting at the intersection of Hearables, Digital Assistants and
Online Eyewear markets, Lucyd is positioned to potentially
become a major player
in eyewear by offering the only
designer smart frames with Rx lenses at an unbeatable price.

Tekcapital ownership
of Lucyd Ltd*

100%

2019,

Lucyd

*In August,

Ltd
incorporated Innovative Eyewear Inc
to optimize its go to market strategy
in the United States. Lucyd Ltd owns
appx 80% of Innovative Eyewear Inc.
as of March 1, 2022.

To provide a unique, new wearable experience, Lucyd has
developed a voice-based social media app called Vyrb™. Vyrb
will enhance Lucyd frames with social features, such as verbal
posting and hashtagging. Lucyd has received a notice of
allowance from the U.S. Patent and Trademark Office on
several features of Vyrb, two utility patents regarding wearable
tech, one of which has been granted a notice of allowance and
38 design patents either pending or issued.

Backed by brand ambassadors Monique Billings (WNBA star),
Chris Clark, (PGA golfer) and Hadar Adora (musician), we
believe that Lucyd offers amongst
the best and most
affordable smart glasses in the market – in 20 fashion forward
designs, designed for all-day wear and available in any
prescription.

The Lucyd brand of smart glasses are now available in 200
optical stores, and on Amazon, BestBuy.com (both U.S. and
Canada) and has been recently been accepted for listing on
DicksSportingGoods.com, the largest sporting goods retailer in
the U.S.

Innovative Eyewear, Inc. Lucyd’s operating subsidiary has filed
an S1 with the U.S. SEC for a potential IPO and NASDAQ
listing, which it seeks to consummate as soon as practicable.

Photo courtesy of Innovative Eyewear, Inc.

P O R T F O L I O R E V I E W

DELI VERI NG I NNOVATI VE OXYGEN
TREATMENT DEVI CES

Unique medical device company that has developed an
improved portable oxygen concentrator to provide on-the-go
supplemental O² for COPD patients.

The company received FDA clearance for their X-PLO2R™
portable oxygen concentrator in March 2021.

We believe their innovative device will be helpful in addressing
COVID-related respiratory problems as well as COPD.
Belluscura recently filed a patent application covering devices
and systems for
treating people suffering from acute
respiratory distress (ARDS) caused by the Coronavirus.
Beyond their current POC, Belluscura is working to design and
develop an improved, portable ECMO technology to treat
ARDS patients.

Capable & highly experienced management: Bob Rauker,
CEO (previously Boston Scientific), Dr Raymond Bray, VP
(previously St. Jude Medical), Keith Cook, V.P. Operations
(previously Inogen).

Belluscura completed its IPO on the AIM on May 28, 2021, to
finance and accelerate the manufacture and sale of
their
portable oxygen concentrators to meet current market
demand.

Belluscura has field or licensed 26 patents to-date, covering
devices and systems for treating people suffering from acute
respiratory distress caused by COPD or the Coronavirus.

To-date they have onboarded 10 distributors and are
accelerating unit sales of their portable oxygen concentrator,
which began in Sept. 2021.

E X P L O 2 R E P O R T A B L E
O X Y G E N C O N C E N T R A T O R

Light:
Efficient:

Quiet:

Reliable:

Modular:

Low Cost:

Strong IP:

Only 1.25kg (2.8lbs)

32% more O2 per pound

Only 39 decibels

Long battery duration

First FDA cleared POC
with consumer replaceable filter cartridges

Projected 70% cost savings over
duration of the disease vs. existing
portable oxygen concentrators
26 patents and applications

The medical portable O2 market is expected to
grow from U$1.4bn this year to US$2.4bn by
2024¹

$1.83bn

$2.01bn

$2.41bn

$2.21bn

$1.51bn

$1.66b
n

$1.40bn

2018 2019 2020 2021 2022 2023 2024

¹ https://www.gminsights.com/industry-analysis/medical-oxygen-

concentrators-market-report

Tekcapital ownership

~ 1 5%

P O R T F O L I O R E V I E W

SOFTWARE PLATFORM FOR REMOTE
MONI TORI NG AND CONTROL OF
AUTONOMOUS VEHI CLES AND DELI VERY
DEVI CES.

With its proprietary software, a world-class team, and portfolio
of seven patents, Guident will be able to deliver competitive
advantages for AV fleet operators by providing real-time
passenger & delivery vehicle monitoring and control, for public
and private mobility markets.

Guident’s initial goal
is to build and operate its first Remote
Monitoring and Control Centre for ground-based delivery
devices and AVs in the State of Florida. Recent state law
requires back-up, human remote monitoring for AVs when a
safety driver is not present in the vehicle. This is a critical path
to enable the commercial
introduction of driverless AVs in
Florida and is likely to be required in other jurisdictions. In 2021
they successfully demonstrated the operation of their RMCC
with industry leading glass-to glass latency of ~38 msec.

Guident also offers an additional patented technology enabling
OEM’s to increase the range of
their electric vehicles with
electromagnetic regenerative shock absorbers. This technology
received the R&D 100 Award by R&D Magazine, for one of the
100 most significant technology innovations of the year from
around the world. Guident has designed and manufactured the
first generation of their regenerative shocks and is currently
testing them for power generation and durability. Multiple
electric vehicle companies have expressed an interest
in
testing the shock absorbers.

Tekcapital ownership of
Guident Ltd

100%

TOTAL
ADDRESSABLE
MARKET

CAGR

$445B¹

83%¹

Guident’s remote monitoring and control of
AV’s covered by multiple issued and
pending patents.

S O U R C E
¹ Global Market Monito Report : “ Global Self-Driving and Driverless Cars Market Professional
Research Report 2015-2027

P O R T F O L I O R E V I E W

GUIDENT APPOINTED HARALD BRAUN AS ITS CHAIRMAN & CEO.
MR. BRAUN HAS SERVED AS CEO OF SIEMENES NETWORK USA
(NYSE: SI) AND AVIAT NETWORKS (NASDAQ: AVNW). HE SERVED
ALSO AS A SENIOR EXECUTE AT NOKIA SIEMENSE NETWORKS,
NORTH AMERICA.

ON 6TH DECEMBER 2018 GUIDENT LTD APPOINTED JOHAN
DE NYSSCHEN AS A DIRECTOR. JOHAN PREVIOUSLY
SERVED AS EXECUTIVE VICE PRESIDENT OF GENERAL
MOTORS AND PRESIDENT OF THE CADILLAC MOTOR
DIVISION, PRESIDENT OF INFINITI MOTOR COMPANY LTD,
PRESIDENT OF AUDI OF AMERICA INC., AND PRESIDENT
OF AUDI JAPAN.

ON 14TH JANUARY, 2019 GUIDENT LTD APPOINTED DANIEL
GROSSMAN AS A DIRECTOR. HE RECENTLY SERVED AS CEO
OF CHARIOT. PREVIOUSLY, DAN HELPED CREATE GENERAL
MOTORS’ MOBILITY DIVISION,
“MAVEN”, AND LED ALL
OPERATIONS AS COO, AND WAS A VICE PRESIDENT AT
ZIPCAR, WHERE HE HELPED PIONEER THE BRAND GLOBALLY.
ZIPCAR WAS SUBSEQUENTLY SOLD TO AVIS-BUDGET FOR ~
$500M.

S T R A T E G I C R E P O R T

Chairman’s S u m m a r y

Tekcapital brings new scientific innovations from
to enhance safety and health and
lab to market
improve the quality of
the customers we
serve. In the past year, thankfully all of our portfolio
companies have made significant advancements
and our strong returns on invested capital continue
and net asset growth has followed in lock step.

life of

Key Portfolio companies

our

global

intellectual properties that

university
proprietary
Leveraging
network, we provide services to universities and
companies to help them assess and commercialise
their innovations. Utilising these services, we have
built a valuable group of portfolio companies to
commercialise select
if
successfully commercialised could make a positive
impact on people’s lives. Our model
is simple, we
seek to couple commercialisation ready, compelling
university IP with visionary management. We then
invest our own capital and introduce exogenous
sources of capital to help these companies grow.
When we realise exits through trade sales or IPOs,
the Group’s goal
the
proceeds as a special dividend to our shareholders.

is to distribute a portion of

smart

vehicles,

Our current portfolio companies were all started by
Tekcapital. Whilst few in number, they are diverse
and span multiple sectors including food tech,
and
autonomous
respiratory medical devices. All of our portfolio
companies have in our view, compelling intellectual
properties, capable and inspired management and
address $Billion+, fast growing markets. The entire
is committed to helping these
team at Tekcapital
companies grow to achieve their full potential and
value.

eyewear

In addition to its focus on B2B sales of Microsalt®
to snack food companies, Salarius has launched its
own snack food brand called SaltMe!™. Beginning in
August 2020 they started shipping their first product,
SaltMe!™ potato chips. The product is now in more
the U.S.. The low
than 2,400 stores throughout
sodium ingredient market
is estimated to reach
US$2b¹ by 2027. Tekcapital owns 97.15% of
Salarius and ~80% of its U.S. subsidiary Microsalt
Inc. as of the date of this report.

Lucyd has built a new, smart eyewear business
that combines technology with traditional
eyewear.

In January 2021, Lucyd’s US subsidiary Innovative
Inc launched Lucyd Lyte™,
their most
Eyewear
advanced and compelling Bluetooth® eyewear. This
combines proper prescription, designer
product
glasses with Bluetooth technology that you can use
to answer your phone, listen to music, and talk with
Siri® or Alexa® or Google Voice. The product has
initially been very well received and is available on
multiple ecommerce sites and in 200 retail optical
stores. Lucyd has developed and filed 41 U.S. utility
products.
and
Innovative Eyewear Inc., a U.S. subsidiary of
its
filed a registration
portfolio company Lucyd Ltd,
statement on Form S-1 with the U.S. Securities and
Exchange Commission for a proposed initial public
offering of shares of its common stock in the United
States. Tekcapital currently owns 100% of the share
capital of Lucyd Ltd and approximately 80% of the
share capital of Innovative Eyewear, Inc.

covering

patents

design

their

Salarius is a food tech business that owns a
patented process to produce micron sized salt.

These small crystals dissolve faster on the tongue,
so you need to use less salt, whilst still having the
same salty taste. Less salt means about 50% less
sodium for most applications. Less sodium means a
reduced likelihood of developing high blood
pressure and heart disease,
the world’s number
one cause of premature death.

Innovative Eyewear intends to commence the sale of
its securities in the IPO following completion of the
to market and other
SEC review process, subject
conditions. A copy of
is
available on www.sec.gov. The Company intends the
shares to be listed on the NASDAQ under ticker:
LUCY.

the registration statement

S O U R C E
¹ https://thetalkingdemocrat.com/news/97310/global-sodium-reduction-ingredient-market-is-projected-to-reach-around-us-
2158-7-million-by-the-end-of-2027-at-a-cagr-of-12-2-business-segmentation-by-revenue-and-structure-forecast-2027-
cambria/
² https://www.statista.com/outlook/12000000/109/eyewear/united-states#market-onlineRevenueShare

S T R A T E G I C R E P O R T

Guident owns or holds the exclusive licence to eight patents and applications that we believe can
improve the safety and efficiency of autonomous vehicles and land-based delivery devices.
Guident has demonstrated its beta remote monitoring and control system (RMCC) with ~38 msec latency
which is believed to be amongst the lowest in the industry.

Guident has progressed with its B2B marketing program and seeks to develop partnerships smart city operators,
vehicle OEM’s and fleet operators to provide remote tele-monitoring and control centres for autonomous vehicles
and fleet operators. Additionally, Guident has fabricated its regenerative shock absorbers and commenced
testing.

According to Allied Market Research¹, the global market for autonomous last mile delivery is projected to reach
US$12.9 billion in 2021. Additionally, Guident has a acquired an exciting, new regenerative shock absorber
technology, to help extend the range of electric vehicles. Guident has executed NDA’s with two listed OEM’s to
test
these new shocks for potential use in their electric vehicles and has fabricated prototypes for testing.
Tekcapital owns 100% of Guident and 96% of its U.S. subsidiary Guident Corporation as of 30 November 2021.

Belluscura has developed and sells an improved portable oxygen concentrator to provide on-the-go
supplemental) O² (oxygen), with user replaceable filter cartridges.

When a patient’s disease progresses, they now can upgrade the filter cartridge to provide more liters of O² per
minute, like adding memory on a laptop, rather than having to replace an expensive medical device. These cost
savings will be beneficial to patients and insurance companies and should help make portable respiratory device
more affordable which is core to Belluscura’s mission. Belluscura filed for and received 510(K) clearance from the
US FDA in March 2021.

On 28th May 2021 Belluscura successfully floated on the AIM to finance and accelerate the manufacture and
distribution of their portable oxygen concentrators. They are performing well and are manufacturing and delivering
units in excess of their anticipation. According to Global Market Insights, the medical portable O² market is
currently $1.4bn² a year and growing by more than US$100m/year². Belluscura has 18 patents filed or licensed to-
date covering devices and systems for treating people suffering from acute respiratory distress caused by COPD
or the Coronavirus. Tekcapital owns approximately 15% of Belluscura as of the date of this report.

FINANCIAL P E R F O R M A N C E
In 2021, despite the global COVID 19 pandemic and the related social and economic hardship, we are fortunate
that our team is healthy, all of our active portfolio companies made significant progress and the value of our
portfolio holdings increased by 105%. This increase was driven primarily by:


increase in the fair value of our Group’s holding in Belluscura (increase of US$18.8m), as a result of the
successful LSE AIM flotation on 28 May 2021 coupled with commercial progress
increase in the fair value of our Group’s shares in Lucyd Ltd (increase of US$12.5m) driven by
commercial progress and a REG CF crowdfund conducted at a $20m pre-money valuation.
increase in the fair value of our Group’s shares in Salarius Ltd (increase of US$0.7m) driven by
commercial progress and an oversubscribed REG CF crowdfund conducted at a $5m pre-money
valuation.



The Group also recorded a US$3.9m fair value loss from its investment in Guident Ltd, after updating the
valuation methodology to the price agreed between Guident CORP and by investors in the most recent Private
Placement offering at $1 a share.

As a result, for 2021, our net assets increased by approximately 108% to US$68.1m, a record level for our
Group. Total income increased 195% to $29.2m with unrealised profit on the revaluation of investments driving
that increase by $28.1m (2020: $8.7m). Our after-tax profit increased by 243% to $26.4m (2020: $7.7m).

Fundraisings during the period

Early-stage businesses facing large market opportunities need talent, technology and capital to succeed. To
help address this we completed the following fundraises in 2021.

S O U R C E
¹ https://www.alliedmarketresearch.com/autonomous-last-mile-delivery-market
²Global Market Insights: Oxygen Cylinders Market Size and Competitive Market Share & Forecast, 2017 –2024

S T R A T E G I C R E P O R T

On 18 March 2021, the Group announced it had completed a fundraising of £3.8m (US $5.4m) before
expenses, through the issue of, in aggregate 38,000,000 Placing Shares at 10 pence per New Ordinary Share.
On 3 November 2021 the Group announced it had completed a fundraising of £3.0m (US$4.3m) before
expenses, through the issue of, in aggregate 10,714,286 placing shares at 28 pence per New Ordinary Share.

Principal Risks and Uncertainties

The specific financial risks are discussed in the notes to the financial statements. Other risks are as follows:

We believe the principal financial risks and benefits of the business relate to the value and performance of the
Group’s portfolio companies. We believe that the fair value of each portfolio company is a time dependent
valuation that may become impaired if the business does not achieve it milestones, growth trajectory, product
development goals, market acceptance, capital raises or other key performance metrics. Individually and as a
group our portfolio companies have a material impact on our financial performance.

• The risk of individual portfolio company negative performance, in the future, may be ameliorated, as our
portfolio becomes more mature, and when our portfolio companies develop significant capital reserves,
predictable revenues and have demonstrated significant increases in value. Management’s strategy of early
detection and remediation includes continuous monitoring of sales performance, expenses and capital
requirements as well as ongoing assistance in strategic planning and fundraising activities, amongst others.

• The principal operational risk of the business is management’s ability to assist our portfolio companies in
achieving their goals and ultimate exits whilst having a small team and an additional goal of increasing our
service revenues. Management’s strategy of early detection and remediation includes continuous
monitoring of sales performance and expenses, intellectual property position and strategic direction, as well
as ongoing assistance in executive and board recruitment, IP acquisition and fundraising activities, amongst
others.

• The Group is dependent on its executive team and directors for its operations and ultimate success and
there can be no assurance that it will be able to retain the services of these key personnel in the future.
Management’s strategy includes regular review of performance and compensation strategy to help improve
retention of talent along with executive requirement to expand the depth of our management bench.

• The COVID-19 epidemic may produce negative economic activities which could reduce the Group’s
economic performance as a result of supply chain disruptions. Further, until the Group covers all of its
operating costs from service revenue and/or portfolio company exits, it will seek to raise additional capital to
fund operations and provide follow-on investments in portfolio companies. The weighted average cost of
capital may increase as a result of geo-political disruptions and knock-on effects of the COVID pandemic in
the equity markets. Management’s strategy of early detection and remediation includes continuous
monitoring of supply chain needs, establishment of alternative sources of production for key components
and ingredients as well as ongoing fundraising activities when necessary, amongst others.

• The current barbaric and senseless Russian invasion of Ukraine has not had a material

impact on our
business to-date, as far as we can discern at this early juncture, as we do not have direct business
exposure to either Russia or the Ukraine. However, over time the conflict may contribute to inflation of
energy costs and supply chain disruption which could increase the cost and complexity of sourcing
components for some of our portfolio companies. Additionally, due to the conflict and the uncertainty it has
introduced to the capital markets, we had delayed our proposed IPO of Innovative Eyewear as we are
seeking to effectuate the transaction in a somewhat more stable market environment as soon as
practicable. Management’s mitigation measures include regular evaluation of potential supply chain
bottlenecks and the identification of potential redundant suppliers or substitute suppliers for each portfolio
company. We will seek to estimate the potential impact on costs and margins, monitoring distributor and
customer pricing as well as continuous assistance in fundraising,
including need for diversification of
funding strategies to include private as well as public sources of capital.

S O U R C E
¹ https://www.alliedmarketresearch.com/autonomous-last-mile-delivery-market
²Global Market Insights: Oxygen Cylinders Market Size and Competitive Market Share & Forecast, 2017 –2024

S T R A T E G I C R E P O R T

Current Trading and Outlook

We are enthusiastic about the development of Tekcapital’s portfolio companies, their performance to-date and
their prospects to significantly expand in 2022. The Board is confident that continued investment in our
portfolio companies remains the right approach for potential
long-term value creation. Additionally, we are
currently exploring early-stage venture funding for a number of our portfolio companies, to accelerate growth
for these companies.

Whilst the Company is progressing very well, investors should note that net asset values will fluctuate from
period to period due to individual portfolio company performance, valuations and changes in market conditions
and macro-economic financial conditions, including recent Coronavirus pandemic, and that changes in the
value of our portfolio companies can have a significant impact on our NAV, revenue, income and future
prospects.

We are grateful for the patience and support of our shareholders. We are also sincerely appreciative of our
.
dedicated, creative and incredibly hardworking portfolio companies and our corporate team, without whom,
none of the results reported herein would be possible.

Section 172 (1) statement

Our Board ensures that all decisions are taken for the long term, and collectively and individually aims to
always uphold the highest standard of conduct. Similarly, our Board acknowledges that the business can
only grow and prosper over the long-term if it understands and respects the views and needs of the
Company’s investors, customers, employees, suppliers and other stakeholders to whom we are accountable,
as well as the environment we operate within. When making decisions, each director ensures that they act in
the way that would most likely promote the Company’s success for the benefit of its members as a whole,
and in doing so have regard (amongst other matters) to the following matters:

The likely consequences of any decision in the long term

a)
In line with our strategy, Tekcapital’s purpose is to find and invest in exciting new discoveries from our global
university network that can enhance people’s lives. We believe that when you couple commercialisation
ready, compelling university IP with strong senior management, vibrant companies will likely emerge. When
we realise exits the Group’s goal
is to distribute a portion of the proceeds as a special dividend to our
shareholders.

With this in mind, we apply the same high standards of responsible stewardship to our businesses as if we
were to own them forever, and it is this approach to decision making that requires the Directors to have
regard to the likely consequences of decisions in the long-term.

The interests of the Company’s employees

b)
The Board strives to maintain and develop a culture where everyone feels valued and included. The Board
also considers the health, safety and wellbeing of all Tekcapital employees in every day decisions. Feedback
from employees is actively encouraged and is considered a key driver in developing our business activities,
processes and workplace environment. Initiatives to encourage wellbeing are well established and continue to
evolve and are strongly influenced by the workforce. Professional and personal development of employees is
viewed as fundamental to the continued success of the Company.

The need to foster the Company's business relationships with suppliers, customers and others

c)
The Board ensures that the Company’s mission is focused on improving the world with university discoveries,
and focuses on innovations that, if successful, can improve the quality of life of customers we serve.
The Board recognises that it is crucial that we deliver a reliable service to our customers and maintain
excellent relationships with suppliers. The Board also considered near-term demand and how customers’
priorities might change over a longer period of time, including effect of the COVID-19 pandemic.

The impact of the company’s operations on the community and the environment

d)
In their decision making, the Directors need to have regard the impact of the Company’s operations on the
community and environment. The Board plays a constructive role in tackling issues through engagement and
making sure the Company’s investments focus on improving quality of life and attempt to solve significant
health and safety problems facing communities.

S T R A T E G I C R E P O R T

The desirability of the Company maintaining a reputation for high standards of business conduct

e)
The Board recognises that culture, values and standards are key contributors to how a company creates
and sustains value over the longer term, and to enable it to maintain a reputation for high standards of
business conduct. High standards of business conduct guide and assist in the Board’s decision making,
and in doing so, help promote the Company’s success, recognising, amongst other things, the likely
consequences of any decision in the long-term and wider stakeholder considerations. The standards set
by the Board mandate certain requirements and behavior with regards to the activities of the Directors,
the Group’s employees and others associated with the Group.

The need to act fairly as between members of the Company

f)
The Company has one class of ordinary shares, which have the same rights as regards voting,
distributions and on a liquidation. Management are also significant shareholders in the Company, holding
approximately 6% of the register, together putting them in the top 3 shareholders of the Company. On this
basis the Board feels that the executive Directors are fully aligned with shareholders.

Belluscura plc listing

g)
Consistent with the Board’s policy to seek exits, when practicable, for our portfolio companies either
through trade sales or public listings we supported Belluscura’s listing and exercised all our options and
warrants pre-IPO.

Innovative Eyewear Inc listing

h)
We have initiated the process for listing of Lucyd’s US operating company,
Innovative Eyewear Inc.’s
shares to enhance its ability to raise capital and compete effectively in the rapidly developing smart
eyewear market. The listing if successful will also increase the company’s ability to recruit experienced
managers by being able to offer associates stock options grants with a near-term path towards
monetisation.

Fundraising activities

i)
During the course of the period, Tekcapital consummated two fundraises for dual reason of continued
investment in our portfolio companies and to increase our available working capital. The former reason is
consistent with board policies mentioned in our 2020 report.

We are enthusiastic about the development of Tekcapital’s portfolio companies, their performance to-date
and their prospects to significantly expand in 2022. The Board is confident that continued investment in
our portfolio companies remains the right approach for potential long-term value creation. Additionally, we
are currently exploring early-stage venture funding for a number of our portfolio companies, to accelerate
growth for these companies.

COVID-19

j)
For our US operations we required all associates to be vaccinated to enable them to work in our corporate
office. Further we followed the CDC guidelines with regard to social distancing, mask utilisation and
quarantines for those that tested positive for COVID 19 or have COVID 19 like symptoms. For our UK
associates we encouraged them to follow NHS guidelines. All UK associates work remotely.

k) Ukraine crisis
The current Russian invasion of Ukraine has not had a material impact on our business to-date, as far as
we can discern at this early juncture, as we do not have direct business exposure to either Russia or the
Ukraine. However, over time the conflict may contribute to inflation of energy costs and supply chain
disruption which could increase the cost and complexity of souring components for some of our portfolio
companies. Additionally, due to the conflict and the uncertainty it has introduced to the capital markets,
we have delayed our proposed IPO of Innovative Eyewear Inc and seek to effectuate the transaction in a
slightly more stable market environment as soon as practicable.

Brexit

j)
United Kingdom’s withdrawal from the EU and entering into the Trade and Cooperative Agreement with
the EU is not expected to have a significant impact on our business, although in future periods it may
increase our costs to secure intellectual properties.

S T R A T E G I C R E P O R T

m) Greenhouse Gas Emissions
the Companies Act 2006 for an
The 2018 Regulations introduced requirements under Part 15 of
enhanced group of companies, which are defined as large by the Companies Act 2006, to disclose their
annual energy use and greenhouse gas emissions, and related information. The group is not currently
defined as large, but it has chosen to apply the 2018 Regulations. Tekcapital plc itself consumes less than
40MWh and therefore is a low energy user, which negates the need to make detailed disclosures of its
energy and carbon information. Furthermore and taking account of this, it has applied the option permitted
by the 2018 Regulations to exclude any energy and carbon information relating to its subsidiaries where
the subsidiary would not itself be obliged to include if reporting on its own account; this applies to all
subsidiaries within the group.

On the basis of the above, the members of the Board consider, both individually and together, that they
have acted in the way they consider, in good faith, would be most likely to promote the success of the
Company for the benefit of its members as a whole (having regard to the stakeholders and matters set
out in s172(1)(a-f) of the Companies Act 2006) in the decisions taken during the year ended 30 November
2021.

S T R A T E G I C R E P O R T : F I N A N C I A L R E V I E W & K E Y P E R F O R M A N C E
I N D I C A T O R S

T H E K E Y P E R F O R M A N C E INDICATORS (KPIs) F O R T H E G R O U P

The Key Performance Indicators (KPIs) listed below represent those that are typically applied to
companies that seek to commercialise university technologies and serve as a starting point for evaluating
the Group’s performance:

KPI

DESCRIPTION

2021

2020

% change

FAIR VALUE OF
THE PORTFOLIO

Updated value of portfolio
companies using costs,
independent valuations or
observed third party investments

TOTAL INCOME

Total income including revenue
from services, fair value gains, and
other income

$62.5m

$30.5m

105%

$29.2m

$9.9m

PROFIT

After tax profit

$26.4m

$7.7m

NET ASSETS PER
SHARE

Total assets minus total liabilities
per share

ROIC

Returns on invested capital

$0.48

42%

$0.35

23%

N e t A s s e t s ( U S $ m )

2020

$32.7

2019

$22.3

2021

$68.1

P r o f i t a f t e r t a x ( U S $ m )

2019

$5.5

2020

$7.7

195%

243%

37%

83%

2021

$26.4

five Key Performance Indicators showed improvement

All
in 2021. The Group has now demonstrated five
consecutive years of growth in Net Assets. The Group’s cash position at the end of the period is US$3.5m (2020:
US$0.5m) with modest liabilities as costs have been settled without delay using available funds. The Group had no
debt as of 30 November 2021 (2020: US$nil).

Directors do not believe there are any material environmental
2021.

issues that need to be reflected in our KPIs for

The Group has received a R&D Tax Relief Credit of US$90,928 (2020: US$89,050) in connection to the
following R&D activities:

•

The design and development of a unique and first of a kind Innovation Discovery Network solution,
developed to facilitate an improved university technology search engine
The Report Builder to develop and test new invention report templates and revamp the invention evaluator
bespoke software
The Invention Evaluator migration and integration with bespoke customer portal.

The Strategic Report was approved by the Board of Directors on 5 May 2022.

Clifford M. Gross, Ph.D.
Chairman and CEO

5 May 2022

B O A R D O F D I R E C T O R S

Cliff is a successful executive with more than 25 years of leadership
experience in academia and business. He is passionate about
commercialisation of university discoveries to improve the quality of
life. He founded three companies (Biomechanics Corp., UTEK &
Tekcapital) which subsequently listed, where he served as CEO and
Chairman and co-founded numerous private companies including
HumanCAD, Salarius, Belluscura, Lucyd and Guident. Previously he
was President and CEO of Innovacorp, the provincial venture capital
fund of Nova Scotia. Cliff was Acting Director of
the graduate
program in Biomechanics and Ergonomics at New York University,
Chairman of the Nelson Rockefeller Department of Biomechanics at
the New York Institute of Technology and Research Professor at the
University of South Florida. He has authored several books
including Too Good to Fail: Creating Marketplace Value from the
World’s Brightest Minds and is a named inventor on more than 30
issued patents. A number of
the ergonomic products he has
developed became significant commercial successes including the
DeWalt Cordless Drill for Black & Decker, The Parachute Chair for
Knoll, the ergonomic mouse for Logitech, HumanCAD, the first PC
based human CAD software and the flexible back belt, which is used
to reduce back stress for individuals worldwide. Several of his
products were included in a Smithsonian exhibit on ergonomic
design. Cliff is a Fellow of the National Academy of Inventors and
serves on the board of the State University of New York at Empire
State College. He received his Ph.D. from New York University and
an MBA from Oxford University.

Robert practiced at the Mayo Clinic for twenty years, serving as a
Physician-Executive before retiring as an Emeritus Professor in
2019. He served as Vice Chair of the national Mayo Clinic Cancer
Center Practice Committee, overseeing cancer care delivery at all of
Mayo’s national sites, and was Medical Director Particle Therapy at
Mayo Clinic Florida where America’s first carbon ion radiotherapy
facility is being built. He also previously served as Vice Chairman of
the Board of Trustees of the Mayo Clinic Health System – Albert Lea
and Austin. He is the author of over 190 peer-reviewed papers.
Robert has successfully led a series of national, NIH funded Phase
III clinical trials searching for new pharmaceutical solutions to reduce
symptoms of cancer therapy. He is currently Director of Radiation
Oncology at the University of Tennessee in Knoxville, Tennessee.
Robert began his scientific career as a medical physicist at
the
University of Kentucky, before going on to graduate from medical
school at the University of Kentucky. Robert also received an MBA
from Oxford University. He is currently Director of Radiation
Oncology at the University of Tennessee in Knoxville, Tennessee.

The Rt Hon Lord Willetts FRS is President of
the Resolution
Foundation and former Minister for Universities and Science. He
served as the Member of Parliament for Havant (1992-2015), and
previously worked at HM Treasury and the No. 10 Policy Unit. Lord
Willetts is a visiting Professor at King’s College London, Governor of
the Ditchley
the British Science
Association and a member of the Council of the Institute for Fiscal
Studies. He is also an Honorary Fellow of Nuffield College, Oxford.
Lord Willetts has written widely on economic and social policy. His
book ‘The Pinch’, which focused on intergenerational equity, was
and he recently published ‘A University
published in 2010,
Education’. Lord Willetts is a graduate of Oxford university and has
been awarded numerous honorary doctorates.

former Chair of

Foundation,

Registered Office
12 New Fetter Lane
London
EC4A 1JP

Auditor
MacIntyre Hudson LLP
6th Floor
2 London Wall Place
London
EC2Y 5AU

Banks
HSBC plc
Canada Place
Canary Wharf
London E14 5AH

Toronto-Dominion Bank
12620 Biscayne Blvd
North Miami FL
33181 USA

Solicitors
Bird & Bird LLP
12 New Fetter Lane
London EC4A 1JP

Nominated Adviser and Broker
SP Angel Corporate Finance
LLP
Price Frederick House
35-39 Maddox Street
London W1S 2PP

Investor Relations
Flagstaff Strategic and Investor
Communications
1 King Street
London EC2V 8AU

Louis Castro has over 30 years’ experience in investment banking
and broking both in the UK and overseas. Most recently he was the
Chief Financial Officer at Eland Oil & Gas, a mid –cap quoted
company. Previously he was Chief Executive of Northland Capital
Partners in London and before this was Head of Corporate Finance
at Matrix Corporate Capital and at Insinger de Beaufort. He started
his career by qualifying as a Chartered Accountant with Coopers &
Lybrand (now PWC). Louis chairs the Audit Committee and is a
member of the Remuneration Committee. He is a Fellow of the
Institute of Chartered Accountants In England and Wales and has a
Double Degree in
Engineering Production & Economics from
Birmingham University.

D I R E C T O R S ’ REPORT F O R THE YEAR-ENDED 30 NOVEMBER 2021

Directors

The following Directors held office during the period:
Clifford M Gross, Ph.D.
Robert Miller, M.D.
Louis Castro
The RT Hon Lord David Willets FRS

The Group has chosen to set out in the groups strategic report information required to be contained in the
directors’ report. It has done so in respect of future developments. The principal activity of the parent
company is that of an investment entity.

Statement of Directors’ responsibilities

The Directors are responsible for preparing the financial statements in accordance with applicable laws and
regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the
Directors have elected to prepare the financial statements in accordance with International Financial Reporting
Standards adopted by the Companies Act 2006 ("IFRS") and those parts of the Companies Act 2006 relevant to
companies which apply IFRS. Under company law, the Directors must not approve the financial statements
unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit
or loss of the Company for that year. In preparing those financial statements, the Directors are required to:

• select suitable accounting policies and then apply them consistently;

• make judgments and estimates that are reasonable;

• state whether applicable accounting standards have been followed, subject to any material departures disclosed
and explained in the financial statements; and

• prepare the financial statements on the going concern basis unless it is inappropriate to presume that the
Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the
Company’s transactions and disclose with reasonable accuracy at any time the financial position of the Company
and to enable them to ensure that the financial statements comply with the Companies Act 2006. The Directors
are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the
prevention and detection of fraud and other irregularities.

Each of the current Directors, whose names are listed in the Directors’ report on this page of the financial
statements confirm that, to the best of each person’s knowledge and belief:
•

the financial statements, prepared in accordance with UK-adopted international accounting standards, give
a true and fair view of the assets, liabilities, financial position and profit (or Loss) of the Group and
Company; and
the chairman’s statement contained in the annual
the
development and performance of the business and the position of the Group and Company, together with a
description of the principal risks and uncertainties that they face.

financial statements includes a fair review of

•

The Directors are responsible for the maintenance and integrity of the corporate and financial information
included on the Group’s website www.tekcapital.com. Legislation in the United Kingdom governing the
preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Going Concern

The Group meets its day to day working capital requirements through its service offerings, cash at bank and
monies raised in follow-on offerings. The Group’s forecasts and projections indicate that the Group has
sufficient cash reserves to operate within the level of its current facilities. Whilst it is the Group’s intention to
rely on the available cash reserves,
future income generated from its growing service offerings and
reductions in its cost base, a negative variance in the forecasts and projections would make the Group’s
ability to continue as going concern dependent on an additional fund raise or monetization of certain assets.

D I R E C T O R S ’ REPORT F O R THE YEAR-ENDED 30 NOVEMBER 2021

The Group has access to equity markets if it seeks additional funds. Whilst the COVID-19 epidemic is
impact is difficult to measure, at the time of
contributing to uncertainty in the markets and the full
approving the accounts after making enquiries, the Directors have a reasonable expectation that the
Group has adequate resources to continue in operational existence for the foreseeable future.

Information has been included in the strategic report in relation to disclosures under S414C(11) of the
Companies Act 2006.

Dividends
No dividend was paid or was proposed during the year ended 30 November 2021 (2020: $nil).

Audit Committee
The Board operates an Audit Committee, chaired by Louis Castro. This Committee carries out
in the AIM Admission Document, supervising the financial and reporting
duties as set out
arrangements of
consider
appropriate to disclose in their Report.

the Group. During the period, no issues arose that

the Directors

Remuneration Committee
The Board has delegated to its Remuneration Committee, chaired by Dr Robert Miller, certain
responsibilities in respect of the remuneration of senior executives. During the period, no issues arose that
the Directors consider appropriate to disclose in their Report.

Directors’ Emoluments

Director’s proportion of the stock option expense is below US$20,000. The Group did not make any
contributions to a pension scheme in the year ended 30 November 2021 (2020: Nil). Directors’ beneficial
interests in shares

Please note the above figure for Clifford M Gross does not include 100,000 shares held by both of Dr. Gross’s
adult children who are not considered a PCA as defined in the Article 3(1)(26) of the UK Market Abuse Regulation.

The details of the options held by each director at 30 November 2021 are as follows:

D I R E C T O R S ’ REPORT F O R THE YEAR-ENDED 30 NOVEMBER
2021

* The options vest in three equal annual instalments from the date of grant and there is a special condition
which means the options will vest when the closing price for a share has been traded at more than 50
pence (sterling) for ten consecutive trading days.
** The options shall vest when the net asset value, as stated in the annual consolidated accounts,
meets, or exceeds USD$20.53m during the 36 months after the grant date. The threshold shall be re-
tested when each set of accounts published during the 36 months are finalised.
An additional 525,000 options were held by Harrison Gross, family member of Dr. Clifford Gross.

Principal Risks and Uncertainties

Please refer to strategic report.

Post Balance Sheet Events

For further details, please refer to note 27 in the notes to the accounts. Information has been
included in the strategic report under S414C(11).

For activities in field of research and development, please refer to Strategic report.

For financial instruments risks, please refer to Note 3.1 of the Notes to the Financial Statements.

D I R E C T O R S ’ REPORT F O R THE YEAR-ENDED 30 NOVEMBER 2021
C O R P O R A T E G O V E R N A N C E

The Tekcapital board is committed to maintaining high standards of corporate governance. In accordance
the corporate
with AIM Rule 26, AIM quoted companies are required to adopt and give details of
governance code which they have adopted and to show how they are following it. The board has adopted
the Quoted Companies Alliance’s (QCA) Corporate Governance Code for small and mid-size quoted
companies (the “QCA Code”).

Of the recognized codes generally adhered to by AIM companies, the QCA Code has been drafted with
smaller businesses in mind, with a pragmatic and principles-based approach. It was therefore deemed by
the board to be the most suitable.

Solid corporate governance is the foundation on which the business is managed, and this is supported by
the range of talents of the directors. Biographies of the directors appear on page 27 and demonstrate a
range of experience and caliber to bring the right level of independent judgment to Tekcapital’s business.
Ensuring financial strength alongside the growth of portfolio businesses are key guiding principles,
supported by an effort to ensure solid communication with shareholders.

The chairman is responsible for leading the board and for its overall effectiveness in directing the group.
They ensure that the board implements, maintains and communicates effective corporate governance
processes and promotes a culture of openness and debate designed to foster a positive governance culture
throughout the group.

The board is responsible for the group’s system of internal control and for reviewing its effectiveness. Such
a system can only provide reasonable, but not absolute, assurance against material misstatement or loss.
The board believes that the group has internal control systems in place appropriate to the size and nature of
its business. The board is satisfied that the scale of the group’s activities does not warrant the establishment
of an internal audit function.

The board is also responsible for identifying the major business risks faced by the group and for determining
the appropriate course of action to manage those risks. Formal meetings are held quarterly to review
strategy, management and performance of
the group, with additional meetings between those dates
convened as necessary. During 2021, all directors attended all quarterly meetings either in person or by
conference call. The QCA Code identifies ten principles that focus on the pursuit of medium- to long-term
value for shareholders without stifling entrepreneurial spirit. Tekcapital’s adoption of the QCA principles is
summarized in the table below. Further details are made available on our website at
https://www.tekcapital.com/investors/#section-ecc78d7-5.

QCA principle

Tekcapital adoption

Establish a strategy and
business model
which
promote long-term value for
shareholders

Tekcapital’s mission is to transform university discoveries into
valuable products. Our investment objective is to achieve long-
term growth of net assets and returns on invested capital through
the commercialisation of university discoveries that can make a
positive impact on people’s lives. We believe the combination of
these factors will maximize long-term value for shareholders.

Seek to understand and
meet
shareholder needs
and expectations

The board engages with shareholders and the broader
investment community via a variety of channels and activities
including the annual general meeting, updates to shareholders
via reporting and the regulatory news service, and institutional
presentations. The Chairman and CEO are the primary contacts
for investor interaction alongside SP Angel.

D I R E C T O R S ’ REPORT F O R THE YEAR-ENDED 30 NOVEMBER 2021
C O R P O R A T E G O V E R N A N C E

QCA principle

Tekcapital adoption

and

Take into account wider
stakeholder
social
responsibilities and their
implications for
long-term
success

Tekcapital’s culture is very open and this includes reaching out and
seeking feedback and insights from our various stakeholders.
In
addition to the investor outreach described above, key practical
elements of this philosophy for other stakeholders include having a flat
organization with few tiers of management, meeting regularly; all-
hands communications via web-meetings; engagement with portfolio
companies through regular meetings, satisfaction surveys.

effective

Embed
risk
management, considering
and
opportunities
both
the
throughout
threats,
organization

The board is responsible for identifying the major business risks faced
by the group and for determining the appropriate course of action to
manage those risks. The board has adopted a framework for the
effective identification, assessment, and management of risks to the
achievement of corporate objectives. The risks that the board consider
to be principal risks to the group’s business and how they are
mitigated are set out on page 22 of the Strategic Report.

Maintain the board as a
well-functioning, balanced
team led by the chair

The QCA Code requires that boards have an appropriate balance
between executive and non-executive directors and that each board
should have at least two independent directors. The board is made up
of one executive director and three non-executive directors. The non-
executive directors are mature, experienced and independent persons
who have each succeeded in their own businesses and are not
dependent upon income from the group. They have developed a
strong and detailed understanding of the business, and are prepared
and able to intervene and challenge the executive director.

Ensure that between them
the directors have the
up-to-date
necessary
and
experience,
capabilities

skills

based

Evaluate
performance
clear
objectives,
continuous improvement

board
on
relevant
seeking

and

Promote
culture that
ethical
behaviours

corporate
is based on
and

values

the directors of

the background and experience of

Details of
the
company are set out on page 27 of this report. These demonstrate
that our team collectively has the necessary skills and experiences, as
well as the required caliber, to carry out the group’s strategy and
business model effectively. The non-executive directors comprise an
investment specialist, a professor and pharmaceuticals specialist, and
a former minister
three have
for universities and science. All
experience of working in a public company environment.
A board self-evaluation process led by the chairman takes place every
three years, using a QCA-sponsored questionnaire and process. Low
scoring or divergent scoring responses are discussed, with gaps and
actions for improvement identified.

Tekcapital’s core values statement and guiding principles, developed
by the extended management team, support the group’s culture with a
strong footing in ethical values. These are reinforced in the staff
handbook and the staff appraisal and development process, which
formally embeds cultural and ethical considerations as part of each
employee’s self-evaluation.

D I R E C T O R S ’ REPORT F O R THE YEAR-ENDED 30 NOVEMBER 2021

QCA principle

Tekcapital adoption

Maintain
governance
structures and processes
that are fit for purpose and
support
decision-
good
making by the board

Formal board meetings are held quarterly to review strategy,
management and performance of
the group, with additional
meetings between those dates convened as necessary. We have
two
the
committees,
Remuneration Committee.

the Audit Committee

board

and

how

the
Communicate
company is governed and
is
by
performing
maintaining a dialog with
other
shareholders
relevant stakeholders

and

The group’s approach to investor and shareholder engagement is
reports, Annual
described under Principle 2 above. Annual
General Meeting notices,
trading
updates and other governance-related are available from the
group’s website.

regulatory announcements,

Independent auditors

HW Fisher LLP resigned as auditors and MacIntyre Hudson LLP were appointed as auditor to the
Group and the Company and in accordance with section 485 of the Companies Act 2006.

Statement of disclosure of information to auditors

Each of the persons who was a Director at the date of approval of this report confirms that:

• so far as the Director is aware, there is no relevant audit information of which the Company’s auditor is
unaware; and the Director has taken all the steps that he ought to have taken as a Director in order to
make himself aware of any relevant audit information and to establish that the Company’s auditor is
aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the
Companies Act 2006.

By order of the Board of Directors and signed on behalf of the Board

Louis Castro
Director

5 May 2022

IN D E P E ND ENT A U D ITO R ’S R E P O R T TO TH E ME MB E R S O F
TE K C A P ITA L P LC

Independent auditors’ report to the members of Tekcapital plc

For the purpose of this report, the terms “we” and “our” denote MHA MacIntyre Hudson in relation to
UK legal, professional and regulatory responsibilities and reporting obligations to the members of
Tekcapital plc. For the purposes of the table on pages 36 to 37 that sets out the key audit matters and
how our audit addressed the key audit matters, the terms “we” and “our” refer to MHA MacIntyre
Hudson. The group financial statements, as defined below, consolidate the accounts of Tekcapital plc
and its subsidiaries (the “group”). The “parent company” is defined as Tekcapital plc. The relevant
legislation governing the parent company is the United Kingdom Companies Act 2006 (“Companies
Act 2006”).

Our opinion

We have audited the financial statements of Tekcapital plc for the year ended 30 November 2021.

The financial statements that we have audited comprise:

•
•
•
•
•

Consolidated statement of comprehensive income
Consolidated and company statements of financial position
Consolidated and company statements of changes in the equity
Consolidated statement of cash flows
Notes to the consolidated financial statements, notes to the parent company financial
statements, including the accounting policies.

the group financial
The financial reporting framework that has been applied in the preparation of
statements is International Financial Reporting Standards adopted by the Companies Act 2006
("IFRS") and those parts of the Companies Act 2006 relevant to companies which apply IFRS, The
financial reporting framework that has been applied in the preparation of the parent company financial
statements is applicable law and United Kingdom Accounting Standards, including FRS101 “Reduced
Disclosure Framework” (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

•

give a true and fair view of the state of the group’s and of the parent company’s affairs as at 30
November 2021 and the group’s profit for the year then ended;
the group financial statements have been properly prepared in accordance with International
Financial Reporting Standards adopted by the Companies Act 2006 ("IFRS") and those parts of
the Companies Act 2006 relevant to companies which apply IFRS;
the parent company financial statements have been properly prepared in accordance with
United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.

Our opinion is consistent with our reporting to the Audit Committee.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and
applicable law. Our responsibilities under those standards are further described in the Auditor’s
Responsibilities for the Audit of the Financial Statements section of our report. We are independent of
the group in accordance with the ethical requirements that are relevant to our audit of the financial
statements in the UK, including the FRC’s Ethical Standard as applied to listed entities, and we have
fulfilled our ethical responsibilities in accordance with those requirements. We believe that the audit

evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

IN D E P E ND ENT A U D ITO R ’S R E P O R T TO TH E ME MB E R S O F
TE K C A P ITA L P LC

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors’ use of the going concern basis of
accounting in the preparation of the financial statements is appropriate.

Our evaluation of the Directors’ assessment of the group and parent company’s ability to continue to adopt
the going concern basis of accounting included:

• The consideration of inherent risks to the group and parent company’s operations and specifically its
business model and the evaluation of how those risks might impact on the group and parent company’s
available financial resources.

• Evaluating the directors’ assessment of the group’s ability to continue as a going concern, including an
examination of cash flow forecasts, challenging the underlying data and key assumptions in those
forecasts, being the level of sales and administrative expenses, used to make the assessment and
comparing these to historical performance and post year-end information.

• Examining management’s budgets and forecasts and their basis of preparation, including review and
assessment of
the model’s appropriateness, mechanical accuracy and the reasonableness of
assumptions included within, including sensitivity analysis on key cash changes from movements in key
assumptions.

• Consideration of availability of funds required to settle obligations, as they fall due, during the going
concern review period. Assessing the reasonableness and practicality of
the mitigation measures
identified by management in their conservative case scenario and considered by them in arriving at their
conclusions about the existence of any uncertainties in respect of going concern.

• Additionally, we reviewed and challenged management’s budgets and forecasts to assess the
reasonableness of the economic assumptions in light of the impact of COVID-19 and the potential impact
of the Ukraine / Russia conflict (including economic sanctions) and the effects on the group’s solvency
and liquidity position.

Based on the work we have performed, we have not identified any material uncertainties relating to events or
conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as
a going concern for a period of at least twelve months from when the financial statements are authorised for
issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the
relevant sections of this report.

Overview of our audit approach

I N D E P E N D E N T AUDITOR’S R E P O R T T O T H E M EM BERS O F
TE K C A P I TA L P L C

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgement, were of most significance in our
audit of the financial statements of the current period and include the most significant assessed risks of
material misstatement (whether or not due to fraud) that we identified. These matters included those matters
which had the greatest effect on: the overall audit strategy, the allocation of resources in the audit; and
directing the efforts of the engagement team and, as required for public interest entities, our results from
those procedures. These matters were addressed in the context of our audit of the financial statements as a
whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters..

IN D E P E ND ENT A U D ITO R ’S R E P O R T TO TH E ME MB E R S O F
TE K C A P ITA L P LC

in aggregate, would change or

Our application of materiality
Our definition of materiality considers the value of error or omission on the financial statements that,
individually or
influence the economic decision of a reasonably
knowledgeable user of those financial statements. Misstatements below these levels will not necessarily
be evaluated as immaterial as we also take account of the nature of identified misstatements, and the
particular circumstances of their occurrence, when evaluating their effect on the financial statements as a
whole. Materiality is used in planning the scope of our work, executing that work and evaluating the

results.

IN D E P E ND ENT A U D ITO R ’S R E P O R T TO TH E ME MB E R S O F
TE K C A P ITA L P LC

Materiality in respect of the Group was set at $400,000 (2020: $227,000) which was determined based
on 1% of Gross Assets calculated prior to any proposed uplift in the fair value of investments in the
current year. Gross assets were deemed to be the most appropriate metric for materiality as this is
primarily what the users of the financial statements are concerned with. We have stripped out any
proposed uplift in the fair value of assets in the current year in our calculations as these considerably
inflate the group’s gross assets and as at the planning stage of our audit these fair value uplifts had yet
to be audited and verified.

Performance materiality is the application of materiality at the individual account or balance level, set at
an amount to reduce to an appropriately low level the probability that the aggregate of uncorrected and
undetected misstatements exceeds materiality for the financial statements as a whole.

Performance materiality for the Group was set at $280,000 (2020: $181,600) which represents 70%
(2020: 80%) of the above materiality levels.

The determination of performance materiality reflects our assessment of the risk of undetected errors
existing, the nature of the systems and controls and the level of misstatements arising in previous audits
Materiality in respect of the parent was set at $160,000 (2020: $86,000) which was determined based
on 1% of Gross Assets calculated prior to any proposed uplift in the fair value of assets in the current
year (2020: 1% of Gross Assets). Performance materiality for the parent company was set at $112,000
(2020: $68,800) which represents 70% (2020: 80%) of the above materiality levels.

We agreed to report any corrected or uncorrected adjustments exceeding $20,000 to the Audit
Committee as well as differences below this threshold that in our view warranted reporting on qualitative
grounds.

The scope of our audit
Our group audit was scoped by obtaining an understanding of the group and its environment, including
the group’s system of internal control, and assessing the risks of material misstatement in the financial
statements. We also addressed the risk of management override of
including
assessing whether there was evidence of bias by the directors that may have represented a risk of
material misstatement.
The group consists of three reporting components. Tekcapital plc and Tekcapital Europe Limited were
considered to be significant components of the Group and were subjected to full scope audits for the
purposes of our audit
reporting component,
report on the group financial statements. The final
Tekcapital LLC, was not considered to be a significant component of the group and thus specified
procedures on all balances in excess of component materiality were undertaken.

internal controls,

Reporting on other information
The other information comprises the information included in the annual report other than the financial
statements and our auditor’s report thereon. The directors are responsible for the other information
contained within the annual report. Our opinion on the financial statements does not cover the other
information and, except to the extent otherwise explicitly stated in our report, we do not express any
form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing
so, consider whether the other information is materially inconsistent with the financial statements or our
knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we
identify such material inconsistencies or apparent material misstatements, we are required to determine
whether this gives rise to a material misstatement in the financial statements themselves. If, based on
the work we have performed, we conclude that there is a material misstatement of this other information,
we are required to report that fact.

We have nothing to report in this regard.

IN D E P E ND ENT A U D ITO R ’S R E P O R T TO TH E ME MB E R S O F
TE K C A P ITA L P LC

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:
•

the information given in the strategic report and the directors’ report for the financial year for which the
financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors’ report have been prepared in accordance with applicable legal

•

requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment
obtained in the course of the audit, we have not identified material misstatements in the strategic report or the
directors’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006
requires us to report to you if, in our opinion:

•

•
•

adequate accounting records have not been kept by the parent company, or returns adequate for our
audit have not been received by branches not visited by us; or
the financial statements of the parent company are not in agreement with the accounting records and
returns; or
certain disclosures of directors’ remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the directors’ responsibilities statement, the directors are responsible for the
preparation of the financial statements and for being satisfied that they give a true and fair view, and for such
internal control as the directors determine is necessary to enable the preparation of financial statements that
are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group’s and the parent
company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern
and using the going concern basis of accounting unless the directors either intend to liquidate the group or the
parent company or to cease operations, or have no realistic alternative but to do so.

Auditors responsibilities for the audit of financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free
from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our
opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in
accordance with ISAs (UK) will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they
could reasonably be expected to influence the economic decisions of users taken on the basis of these
financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design
procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of
irregularities, including fraud.

IN D E P E ND ENT A U D ITO R ’S R E P O R T TO TH E ME MB E R S O F
TE K C A P ITA L P LC

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including
those leading to a material misstatement in the financial statements or non-compliance with regulation. This
risk increases the more that compliance with a law or regulation is removed from the events and transactions
reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance.
The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves
intentional concealment, forgery, collusion, omission or misrepresentation.

The specific procedures for this engagement and the extent
irregularities, including fraud is detailed below:

to which these are capable of detecting

•

Obtaining an understanding of the legal and regulatory frameworks that the group operates in, focusing
on those laws and regulations that had a direct effect on the financial statements. The key laws and
regulations we considered in this context included the reporting framework, rules of the London Stock
Exchange for companies trading securities on AIM,
the Companies Act 2006 and applicable tax
legislation.

We obtained an understanding of how the group is complying with those frameworks by making
enquiries of management, those responsible for legal and compliance procedures and the Company
Secretary. We corroborated our enquiries through our review of board minutes and papers provided to
the Audit Committee.

We assessed the susceptibility of the group’s financial statements to material misstatement, including
how fraud might occur, by meeting with group management to understand where they considered there
was a susceptibility to fraud and to identify any instances of known or suspected instances of fraud;

Our audit planning identified fraud risks in relation to management override, valuation of unquoted
equity investments and inappropriate or incorrect recognition of revenue (valuation of unquoted equity
investments and revenue recognition are assessed as a Key Audit Matters above). We obtained and
understanding of the processes and controls that the group has established to address risks identified,
or that otherwise prevent, deter and detect fraud; and how management monitors that processes and
controls;

With regards to the fraud risk in management override, our testing included journal transaction testing,
with a focus on large or unusual transactions, evaluating the business rationale of these transactions.
We also performed an assessment on the appropriateness of key judgements and estimates, which are
subject to management’s judgement and estimation, and could be subject to potential bias; and

fraud risks to all
We also communicated relevant
engagement team members and remained alert to any indications of fraud or non-compliance with laws
and regulations throughout the audit.

identified laws and regulations and potential

A further description of our responsibilities for the financial statements is located on the FRC’s website at:
www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the Company’s members, as a body, in accordance with Chapter 3 of Part 16 of
the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company’s
members those matters we are required to state to them in an auditor’s report and for no other purpose. To
the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the
Company and the Company’s members as a body, for our audit work, for this report, or for the opinions we
have formed.

Andrew Gandell FCA
Senior Statutory Auditor

For and on behalf of MHA MacIntyre Hudson
London United Kingdom

5 May 2022

CO NS O LI DATE D STATEM ENT O F CO M PR E HE NS I VE
INCOME F O R T H E Y E A R E NDE D 3 0 NOVEM BER 2021

*Amounts relating to convertible loan note interest income previously included within Revenue from
services were reclassified in 2021 to Interest from financial assets at fair value through profit or loss
(including presentation of prior year balances).

**Amounts relating to R&D relief and government grants (see note 6.1) previously included under
Revenue from services, were reclassified in 2021 to Other income (including presentation of prior
year balances).

*** May be reclassified to profit or loss in future years.

The notes on pages 45 to 77 are an integral part of these consolidated financial statements.

C O N S O L I D A TE D STA TEM ENT O F FI NANCIAL P O SI TI ON AT
3 0 NOVEM BER 2021

The notes on pages 45 to 77 are an integral part of these financial statements.

The financial statements on pages 41 to 77 were approved and authorised for issue by the Board of
Directors on 5 May 2022 and were signed on its behalf.

Louis Castro
Director

Tekcapital PLC
registered number
08873361

Dr Clifford M Gross
Chairman and CEO

CO N SO L I DA TED STATEM ENT O F C H A N G E S IN TH E EQUI TY
F O R TH E Y E A R EN DED 3 0 NOVEM BER 2021

Share premium - amount subscribed for share capital
attributable costs.

in excess of nominal value, net of directly

Translation reserve - foreign exchange differences recognized in other comprehensive i ncome

Other reserve – historic other reserve outside of share premium, translation reserve and share premium

Retained earnings - cumulative net gains and losses recognised in the consolidated statement of
comprehensive income, net of dividends paid.

The notes on pages 45 to 77 are an integral part of these financial statements.

C O N S O L I D A TE D S TA TE M E N T O F C A S H F L O W S F O R T H E
Y E A R E N D E D 3 0 N O V E M B E R 2 0 2 1

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

General Information

Tekcapital PLC (Companies House registration number: 08873361) is a company incorporated in England
and Wales and domiciled in the UK. The address of the registered office is detailed on page 27 of these
financial statements. The Company is a public limited company limited by shares, which listed on the AIM
market of the London Stock Exchange in 2014. The principal activity of the Group is to provide universities
and corporate clients with valuable technology transfer services. The Group also acquires exclusive
licences to university technologies that it believes can positively impact people’s lives, for subsequent
commercialisation.

The principal accounting policies applied in the preparation of these consolidated financial statements
are set out below. These policies have been consistently applied to all the years presented, unless
otherwise stated.

Amounts presented in this report are rounded to nearest US$1.

2.1

Accounting policies

Statement of compliance

The consolidated financial statements of Tekcapital PLC Group have been prepared in accordance with
International Financial Reporting Standards adopted by the Companies Act 2006 ("IFRS") and those parts of
the Companies Act 2006 relevant to companies which apply IFRS. The consolidated financial statements
have been prepared under the historical cost convention. The consolidated financial statements comprise
the financial statements of Tekcapital plc and its subsidiaries, Tekcapital Europe Ltd and Tekcapital LLC.

The preparation of
financial statements in conformity with IFRS requires the use of certain critical
accounting estimates. It requires management to exercise its judgement in the process of applying the
Group’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas
where assumptions and estimates are significant to the consolidated financial statements are disclosed in
note 4.

2.1.1 Going concern

The Group and the Company meets its day to day working capital requirements through its service
offerings and monies raised through the issues of equity. The Group’s forecasts and projections indicate
that the Group and the Company have sufficient cash reserves to operate within the level of its current
facilities. Whilst it is the Group’s and the Company’s intention to rely on the available cash reserves,
future income generated from its growing service offerings and reductions in its cost base, a negative
variance in the forecasts and projections would make the Group’s ability to continue as a going concern
dependent on monetisation of quoted equity stakes or an additional fund raise.

the portfolio or equity issues. Whilst

If the Group’s forecasts are not achieved, the Directors would seek to raise the additional funds through
monetisations of
the COVID-19 epidemic is contributing to
uncertainty in the markets, at the time of approving the accounts after making enquiries, the Directors are
satisfied that the Group and the Company have adequate resources to continue in operational existence
for the foreseeable future. The Group and the Company therefore continue to adopt the going concern
basis in preparing both its consolidated financial statements and for its own financial statements.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

2.1.2 Changes in accounting policy and disclosures

New standards, interpretations and amendments not yet adopted

The Group adopted early the following amendments to standards which are not yet mandatory.

Amendments to IAS 16 Property, Plant and Equipment (issued in May 2020)

The amendments require any proceeds from selling items produced (and related production costs) in the
course of bringing an item property, plant and equipment into operation to be recognised in profit or loss
clarifying that such items are not reflected in the cost of the asset.

The amendment is effective for financial years beginning on or after 1 January 2022 and is not yet
endorsed for use under in UK adopted IFRS under the Companies Act 2006.

The Group does not expect a material
amendments.

impact on its consolidated financial statements from these

Amendments to IAS 37 Provisions, Contingent Liabilities and Contingent Assets (issued in May 2020)

The amendments clarify that the cost of fulfilling a contract are costs that relate directly to that contract.
Such costs can be the incremental costs of fulfilling that contract or an allocation of other costs directly
related to fulfilling that contract.

The amendment is effective for financial years beginning on or after 1 January 2022 and is not yet
endorsed for use in UK adopted IFRS under the Companies Act 2006.

The Group does not expect a material
amendments.

impact on its consolidated financial statements from these

Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-
current (issued January 2020)

The amendments clarify that the classification of a liability as current or non-current is based only on rights
existing at the end of the reporting period and the classification is not affected by expectations about
whether rights to settle or defer a liability will be exercised. Further, the amendments clarify that the
settlement of a liability refers to the transfer of cash, equity instruments, other assets, or services to the
counterparty. This amendment only affects presentation.

The amendment is effective for financial years beginning on or after 1 January 2023 and is not yet
endorsed for use in UK adopted IFRS under the Companies Act 2006.

The Group does not expect a material
amendments.

impact on its consolidated financial statements from these

Amendments to IAS 1 and IFRS Practice Statement 2 Disclosure of Accounting Policies (issued in
February 2021)

The amendments enhance the disclosure requirements relating to an entity’s accounting policies and
clarify that the notes to a complete set of financial statements are required to include material accounting
policy information. Material accounting policy information, when considered with other information included
in the financial statements, can reasonably be expected to influence decisions that the primary users of
financial statements make on the basis of the financial statements. The amendments help preparers
determine what constitutes material accounting policy information and notes that accounting policy
information which focuses on how IFRS has been applied to its own circumstances is more useful for
users of financial statements than standardised information or information duplicating the requirements of
IFRS.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

The amendment also states that immaterial accounting policy information need not be disclosed but when it
if accounting policy
is disclosed it shall not obscure material accounting policy information. Further,
information is not deemed material this does not affect the materiality of related disclosure requirements of
IFRS.

The disclosure of judgements made in applying accounting policies should reflect those that have had the
most significant effect on items recognised in the financial statements.

The amendment is effective for financial years beginning on or after 1 January 2023 and is not yet endorsed
for use under in UK adopted IFRS under the Companies Act 2006.

Amendments to IAS 8 Definition of Accounting Estimates (issued in February 2021)

The amendments define accounting estimates as monetary amounts in financial statements that are subject
to measurement uncertainty. An accounting policy may require an item in financial statements to be
measured at a monetary amount that cannot be observed directly so that in order to achieve the objective of
an accounting policy, an estimation is required.

The amendments state that the development of an accounting estimate requires the use of judgement or
assumptions based on the latest available reliable information and involve the use of measurement
techniques and inputs. Accounting estimates might then need to change as a result of new information, new
developments or more experience.

A change in input or measurement
prospectively unless the change results from the correction of prior period errors.

technique is a change in accounting estimate which is applied

The amendment
endorsed for use in UK adopted IFRS under the Companies Act 2006.

is effective for financial years beginning on or after 1 January 2023 and is not yet

Amendments to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction
(issued 7 May 2021)

The amendments specify how companies should account for deferred tax on transactions such as leases
and decommissioning obligations.

In specified circumstances, companies are exempt from recognising deferred tax when they recognise
assets or liabilities for the first
there had been some uncertainty about whether the
exemption applied to transactions such as leases and decommissioning obligations—transactions for which
companies recognise both an asset and a liability.

time. Previously,

The amendments clarify that the exemption does not apply and that companies are required to recognise
deferred tax on such transactions. The aim of the amendments is to reduce diversity in the reporting of
deferred tax on leases and decommissioning obligations.

The amendments are effective for annual reporting periods beginning on or after 1 January 2023, with early
application permitted and is not yet endorsed for use in UK adopted IFRS under the Companies Act 2006.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

2.1.2 Changes in accounting policy and disclosures

2.2 Business combinations

Tekcapital PLC was incorporated on 3 February 2014 and on 18 February 2014 entered into an
agreement to acquire the issued share capital of Tekcapital Europe Limited by way of share issue. On
19 February 2014 it acquired the issued share capital of Tekcapital LLC also by share issue. This has
been accounted for as a common control transaction under IFRS 3 using the pooling of interest method
by
using the nominal value of shares exchanged in the business combination and no fair value
adjustment.

The consolidated financial statements are accounted for using the ‘pooling of interests’ method’, which
treats the Group as if it had been combined throughout the current and comparative accounting periods.

The consolidated financial statements comprise the financial statements of Tekcapital PLC and all
subsidiaries controlled by it.

Subsidiaries are entities that are controlled by the Group. Control is achieved when the Group has the
power to govern the financial and operating policies of an entity so as to obtain economic benefit from its
activities. Intercompany transactions, balances and unrealised gains on transactions between Group
companies are eliminated. Unrealised losses are also eliminated when necessary amounts reported by
subsidiaries have been adjusted to conform to the Group’s accounting policies.

2.3 Foreign currencies

(a) Functional and presentation currency

These consolidated financial statements are presented in US Dollars which is the presentation currency
of
the Group. The Directors consider this to be the most appropriate presentational currency. Each
subsidiary within the Group has its own functional currency which is dependent on the primary economic
environment in which that subsidiary operates. The functional currency of Tekcapital Plc is UK sterling as
this is the currency the entity undertakes its primary economic activity.

(b) Transactions and balances

Foreign currency transactions are translated into functional currency using the exchange rates
prevailing at the dates of the transactions or valuation where items are re-measured.

Foreign exchange gains and losses resulting from the settlement of such transactions and from the
translation at the year-end exchange rates of monetary assets and liabilities denominated in foreign
currencies are recognised in the income statement. Foreign exchange gains and losses that relate to
cash and cash equivalents are presented in the income statement within ‘finance income or costs’.

The results and financial position of all Group entities (none of which has the currency of a hyper-
inflationary economy) that have a functional currency different from the presentation currency are
translated into the presentation currency as follows:

N O T E S T O T H E FINANCIAL S T A T E M E N T S

(i)

(ii)

(iii)

Monetary assets and liabilities for each balance sheet presented are translated at the closing
exchange rates at the date of that balance sheet.
Income and expense for each income statement are translated at the average rates of exchange
during the period (unless this average is not a reasonable approximation of the cumulative effect of
the rates prevailing on the transaction dates, in which case income and expenses are translated at
the rate on the dates of the transactions)
All resulting exchange differences are recognised in other comprehensive income.

2.4 Investment in subsidiaries

Investments in subsidiaries including Tekcapital Europe Ltd and Tekcapital LLC are recognised initially at cost.
The cost of the investment includes transactions costs. The carrying amounts are reviewed at each reporting
date to determine whether there is any indication of impairment.

2.5

Investment in portfolio companies

Investments in portfolio companies are held at fair value through the profit and loss. Directors’ judgment was
exercised in determination that
the Group meets the following criteria and should be recognized as an
investment entity under IFRS 10 par. 27. Directors re-evaluated the below criteria and concluded they were met
as at 30 November 2021:

• Obtains funds from one or more investors for

the purpose of providing clients with investment

management services

• Commits to its investors that

its business purpose is to invest funds solely for return from capital

appreciation, investment income or both

• Measures and evaluate the performance of substantially all of its investments on a fair value basis.

Tekcapital’s IP search and technology transfer investment services represent investment advisory services,
and therefore Tekcapital Europe Limited and Tekcapital LLC continue to be treated as subsidiaries and are
consolidated in the Group financial statements. These services may be provided to investors, clients and
third parties. The Board considers that the criteria are met in the group’s current circumstances.

The Board envisages that Tekcapital’s shareholder returns will derive primarily from mid to long-term
capital appreciation of a portion of
its intellectual property investments, as well as from providing IP
investment services to clients. Consequently, the Group’s portfolio companies are measured at fair value in
accordance with IFRS 9 as disclosed in Note 2.9.3.

2.6

Property, plant and equipment

Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost
directly attributable to the acquisition of the items. Subsequent costs are
includes expenditure that
included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is
probable that future economic benefits associated with the item will flow to the Group and the cost of the item
can be measured reliably. All other repairs and maintenance are charged to the income statement during the
financial period in which they are incurred. Depreciation of assets are calculated to write off the cost less the
estimated residual value of tangible fixed assets by equal instalments over the estimated useful economic
lives as follows:

Furniture
Computer equipment
Leasehold improvements

3 years
3 years
5 years

The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each
reporting period. The asset’s carrying amount is written down immediately to its recoverable amount if the
assets carrying value is greater than its estimated recoverable amount. Gains and losses on disposals are
determined by comparing proceeds with the carrying amount and are recognised within ‘Other gains /
(losses) – net’ in the income statement. When re-valued assets are sold, the amounts included in other
reserves are transferred to retained earnings.

N O T E S T O T H E FINANCIAL S T A T E M E N T S

2.7

Intangible assets

Intangible assets that are acquired by the Group are stated at cost less accumulated amortisation and
accumulated impairment losses. Amortisation is charged to the administrative expenses in the Statement of
Comprehensive Income on a straight-line basis over the estimated useful lives of intangible assets unless such
lives are indefinite.

(a) Invention Evaluator

This is an intangible asset and a piece of computer software acquired for use by one of the subsidiaries of the
Group.

The estimated useful life of the Invention Evaluator intangible asset is 10 years. The useful life is estimated
based upon management’s best estimate of the expected life of the asset. The useful life is reconsidered if
circumstances relating to the asset change or if there is an indication that the initial estimate requires
revision.

The directors had previously assessed that the Invention Evaluator intangible asset had an indefinite useful
economic life. The directors have reconsidered this assessment during the year under audit and determined
the intangible asset has a finite life of 10 years over which amortisation is to be charged on a straight line
basis. The amortisation charge for the year includes accumulated amortisation charges for prior periods.
The directors are satisfied the adjustment is not material.

(b) Computer software and website development

Costs associated with maintaining computer software programmes and the Company website are recognised
as an expense as incurred. Development costs that are directly attributable to the design and testing of
identifiable and unique software products controlled by the Group are recognised as intangible assets when
the following criteria are met:

(i)
(ii)
(iii)
(iv)
(v)

(i)

it is technically feasible to complete the software product so that it will be available for use;
management intends to complete the software product and use or sell it;
there is an ability to use or sell the software product;
it can be demonstrated how the software product will generate probable future economic benefits;
adequate technical, financial and other resources to complete the development and to use or sell the
software product are available; and
the expenditure attributable to the software product during its development can be reliably measured.

Computer software development costs recognised as assets are amortised over their estimated useful
which do not exceed four years.

lives,

Costs associated with the acquisition of Licences for technologies with the express purpose of developing
them further for a commercial market are recognised as an intangible asset when they meet the criteria for
capitalisation. That is, they are separately identifiable and measurable and it is probable that economic benefit
will flow to the entity.

Further development costs attributable to the licensed technology and recognised as an intangible asset
when the following criteria are met:

(i)

(ii)
(iii)
(iv)
(v)

(vi)

is technically feasible to complete the technology for commercialisation so that

it
available for use;
management intends to complete the technology and use or sell it;
there is an ability to use or sell the technology;
it can be demonstrated how the technology will generate probable future economic benefits;
adequate technical, financial and other resources to complete the development and to use or sell
the technology are available; and
the expenditure attributable to the technology during its development can be reliably measured.

it will be

N O T E S T O T H E FINANCIAL S T A T E M E N T S

(vi)

adequate technical, financial and other resources to complete the development and to use or sell the
technology are available; and
the expenditure attributable to the technology during its development can be reliably measured.

Licences and their associated development costs are amortised over the life of the licence or the underlying
patents, whichever is shorter.

(d) Vortechs Group

This is an intangible asset acquired for use by one of the subsidiaries of the Group. The estimated useful life of
the Vortechs Group intangible asset is 10 years. The useful life is estimated based upon management’s best
estimate of the expected life of the asset. The useful life is reconsidered if circumstances relating to the asset
change or if there is an indication that the initial estimate requires revision.

The directors had previously assessed that the Vortechs Group intangible asset had an indefinite useful
economic life. The directors have reconsidered this assessment during the year under audit and determined the
intangible asset has a finite life of 10 years over which amortisation is to be charged on a straight line basis. The
amortisation charge for the year includes accumulated amortisation charges for prior periods. The directors are
satisfied the adjustment is not material.

2.8

Impairment of non-financial assets

Intangible assets that have an indefinite useful life or intangible assets not ready to use are not subject to
amortisation and are tested annually for impairment. Assets that are subject to amortisation are reviewed for
impairment whenever events or changes in circumstances indicate that
the carrying amount may not be
recoverable. An impairment loss is recognised for the amount by which the asset’s carrying value exceeds its
recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and
value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which
there are largely independent cash inflows, (CGUs). Prior impairments of non-financial assets (other than
goodwill) are reviewed for possible reversal at each reporting date.

2.9

Financial instruments

2.9.1 Classification

The Group classifies its financial assets depending on the purpose for which the asset was acquired.
Management determines the classification of its financial assets at initial recognition.

During the financial year
the Group held investments in portfolio companies classified as equity
investments. They are included in non-current assets and are measured at fair value through profit and loss
in accordance with IFRS 9.

The Group has convertible loan note receivables. These financial assets are classified and measured at
fair value through profit and loss in accordance with IFRS 9.

The directors had previously assessed the convertible loan notes as measured at amortised cost. The
directors have reconsidered this assessment during the year under audit and determined that based
upon the contractual terms the financial asset should be reclassified as fair value through profit and loss.
The convertible loan note includes a conversion feature allowing the holder to convert the note into
equity on a financing event, sale or listing at market price at the date of the event. The directors have
assessed the conversion feature and are satisfied the fair value of this feature is not material.These
financial assets have therefore been reclassified. The directors are satisfied that the resulting change in
valuation method does not result in a material adjustment. These financial assets continue to be
classified as non-current assets.

The Group also has receivables carried at amortized cost. They are included in current assets. The
Group’s service income receivables comprise ‘trade and other receivables’
in the balance sheet, also
held at amortised cost. The Group also has cash and cash equivalents.

All short-term liabilities are measured at cost, the Group does not hold any long-term financial liabilities.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

2.9.2 Recognition and measurement

IFRS 13 defines fair value as the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants at the measurement date.

Loans and receivables are recognised and carried at amortised cost. Financial assets are derecognised
when the rights to receive cash flows from the loans or receivables have been collected, expired or
transferred and the Group has subsequently transferred substantially all risks and rewards of ownership.
Short term financial liabilities are initially measured at fair value and subsequently measured at amortised
cost using the effective interest rate method.

2.9.3 Fair value

Financial instruments are measured at fair value including investments in portfolio companies, cash and
cash equivalents,
trade and other payables, and convertible loan note
receivables. This measurement policy does not apply to subsequent measurement at amortised cost of
short term financial liabilities and trade receivables.

trade and other receivables,

The Group measures portfolio companies using valuation techniques appropriate in the circumstances and
for which sufficient data are available to measure fair value, maximising the use of relevant observable
inputs and minimising the use of unobservable inputs. Our newly adopted fair value valuation policy is as
follows:

The fair value of new portfolio companies is estimated at the cost of the acquired IP or equity plus associated
expenses to facilitate the acquisition.

Existing portfolio companies are valued as follows:

•

If a market transaction such as third-party funding has occurred during the past 12 months we will value
our ownership in the portfolio company at
taking account of any observed
material changes during the period, including quoted prices in active markets (Level 1 input).

this observed valuation,

In the absence of a recent market transaction, fair value will be estimated by alternative methods and
where appropriate by an external, qualified valuation expert. The valuation techniques fall under Level 2 –
Observable techniques other quoted prices and Level 3 - other techniques as defined by IFRS 13.

Due to their short-term nature, the carrying value of cash and cash equivalents, trade and other receivables,
and trade and other payables approximate their fair value.

2.10

Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is a
legally enforceable right to offset the recognised amounts and there is the intention to settle on a net basis or
realise the asset and settle the liability simultaneously.

2.11

Impairment of financial assets

Impairment provisions for current and non-current trade receivables are recognized based on the simplified
approach within IFRS 9 using the lifetime expected credit losses. During this process the probability of the non-
payment of the trade receivables is assessed. This probability is then multiplied by the amount of the expected
loss arising from default to determine the lifetime expected credit loss for the trade receivables. For trade
receivables, which are reported net, such provisions are recorded in a separate provision account with the loss
being recognized within cost of sales in the consolidated statement of comprehensive income. On confirmation
that the trade receivable will not be collectable, the gross carrying value of the asset is written off against the
associated provision.

Financial assets held at amortised cost comprise trade and other receivables, and cash and cash equivalents
in the consolidated statements of financial position.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

2.12

Cash and cash equivalents

In the consolidated statement of cash flows, cash and cash equivalents includes cash in hand, deposits
held at call with other banks, other short term highly liquid investments with maturities of three months or
less from inception.

2.13

Share capital

Ordinary Shares
Ordinary Shares are classified as equity.

Share premium
The share premium account has been established to represent the excess of proceeds over the nominal
value for all share issues,
including the excess of the exercise share price over the nominal value of the
shares on the exercise of share options as and when they occur. Incremental costs directly attributable to the
issue of new ordinary shares and new shares options are shown in equity as a deduction, net of tax, from
the proceeds.

2.14

Trade payables

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course
of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one
year or less (or in the normal operating cycle of business if longer). If not, they are presented as non-current
liabilities.

Trade payables are recognised initially at fair value and subsequently measured at amortised cost using
the effective interest rate method.

2.15

Share based payments

The Group operates a number of equity-settled, share-based compensation plans, under which the entity
receives services from employees as consideration for equity instruments (options) of the Group. The fair
value of the employee services received in exchange for
the grant of options is recognised as an expense.
The total amount to be expensed is determined by reference to the fair value of the options granted:

•

including any market performance conditions;

excluding the impact of any service and non-market performance vesting conditions (for example,
profitability, sales growth targets and remaining an employee of the entity over a specified time period);
and

excluding the impact of any non-vesting conditions (for example the requirement of the employees to
save).

Assumptions about the number of options that are expected to vest include consideration of non-market
vesting conditions. The total expense is recognised over the vesting period, which is the period over which
all of the specified vesting conditions are to be satisfied. At the end of each reporting period, the entity
revises its estimates of the number of options that are expected to vest based on the non-market vesting
conditions. It recognises the impact of the revision to the original estimates, if any, in the income statement,
with a corresponding adjustment to equity.

When the options are exercised, the Group issues new shares. The proceeds received net of any directly
attributable transactions costs are credited to share capital (nominal value) and share premium when the
options are exercised.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

2.16

Current and deferred tax

The tax expense for the year comprises current and deferred tax. Tax is recognised in the consolidated
income statement, except to the extent that it relates to items recognised in other comprehensive income or
directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity,
respectively.

The current income tax charge is calculated on the basis of tax laws enacted or substantively enacted at the
balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable
income. Management periodically evaluates positions taken in tax returns with respect to situations in which
applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis
of amounts expected to be paid to the tax authorities.

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and
liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities
are not recognised if they arise from the initial
recognition of goodwill; deferred income tax is not accounted
for if it arises from initial recognition of an asset or liability in a transaction other than a business combination
that at the time of the transaction affects neither accounting nor taxable profit or loss.

Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively
enacted by the balance sheet date and are expected to apply when the related deferred income tax asset
is realised or the deferred income tax liability is settled.

Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit
will be available against which the temporary differences can be utilised.

Deferred income tax liabilities are provided on taxable temporary differences arising from investments in
subsidiaries except
the temporary
difference is controlled by the Group and it is probable that the temporary difference will not reverse in the
foreseeable future.

deferred income tax liability where the timing of

the reversal of

for

Deferred income tax assets are recognised on deductible temporary differences arising from investments in
subsidiaries only to the extent that it is probable the temporary difference will reverse in full in the future
and there is sufficient taxable profit available against which the temporary difference can be utilised.

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current
tax assets against current
tax liabilities and when the deferred income tax assets and liabilities relate to
income taxes levied by the same taxation authority on either the same taxable entity or different taxable
entities where there is an intention to settle balances on a net basis.

2.17

Provisions

Provisions and any other anticipated foreseen liabilities are recognised: when the Group has a present legal
or constructive obligation as a result of past events; it is probable that an outflow of resources will be
required to settle the obligation; and the amount has been reliably estimated. Restructuring provisions
comprise lease termination penalties, and employee termination payments. Provisions are not recognised
for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement
is determined by considering a class of obligations as a whole. A provision is recognised even if the
likelihood of an outflow with respect to any one item included in the same class of obligations may be
small. Provisions are measured at the present value of the expenditures expected to be required to settle
the obligation using a pre-tax rate that reflects current market assessments of the time value of money and
the risks specific to the obligation. The increase in the provision due to the passage of time is recognised
as an interest expense.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

2.18

Leases

At inception, the Group assesses whether a contract is, or contains, a lease within the scope of IFRS 16.
A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset
for a period of time in exchange for consideration. Where a tangible asset is acquired through a lease,
the Company recognises a right-of-use asset and a lease liability at the lease commencement date.
Right-of-use assets are included within property, plant and equipment.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability
adjusted for any lease payments made at or before the commencement date plus any initial direct costs
and an estimate of the cost of obligations to dismantle, remove, refurbish or restore the underlying asset
and the site on which it is located, less any lease incentives received.

The right-of-use asset
is subsequently depreciated using the straight-line method from the
commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the
lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those
of other property, plant and equipment. The right-of-use asset is periodically reduced by impairment
losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are unpaid at the
commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be
the Company's incremental borrowing rate. Lease payments included in the
readily determined,
measurement of the lease liability comprise fixed payments, variable lease payments that depend on an
index or a rate, amounts expected to be payable under a residual value guarantee, and the cost of any
options that the Company is reasonably certain to exercise, such as the exercise price under a purchase
option, lease payments in an optional renewal period, or penalties for early termination of a lease.

future lease payments arising from a change in an index or rate;

The lease liability is measured at amortised cost using the effective interest method. It is remeasured
when there is a change in:
the
Company's estimate of the amount expected to be payable under a residual value guarantee; or the
Company's assessment of whether it will exercise a purchase, extension or termination option. When the
lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of
the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has
been reduced to zero.

2.19

Revenue recognition

the fair value of

Revenue is measured at
the consideration received or receivable, and represents
amounts receivable for the services supplied, stated net of discounts, and value added taxes. The Group
recognises revenue when the contract is identified, performance obligation is determined, transaction
price (as defined for each service below) is determined and allocated to performance obligation in
accordance with IFRS 15.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

Provision of services

The Group provides following lines of services:

•

Invention Evaluator services: provision of reports assessing potential of any new technology. Revenue is
recognised upon delivery of a complete report, when the report is made available to each customer. Upon
the contractual
access to the report delivered via online portal, customers consume the benefits of
obligation, and the performance obligation is met. Directors consider transaction price to be clearly
determined upon payment of
fixed fee for each report prior to report’s delivery. Directors considered
uncertainty of cash flows from sales to be limited, considering prepayment is made for each report prior to
report’s delivery.

• Tech transfer recruitment services (Vortechs Group): recruitment services specialising in technology
transfer executives. Revenue is recognised upon placement of an executive, when hire is made by
Tekcapital’s customer and the performance obligation is met. Directors consider transaction price to be
clearly determined when both parties agree to placement
fee for each successful hire. Directors
considered uncertainty of cash flows from sales to be limited, considering payments are made by
universities with excellent track record of payments and clear definition of performance obligation upon
which such payment is made.

tax,

• Management services: accounting,

legal and other services provided to portfolio companies.
Revenue is recognized upon delivery of services to each portfolio company and performance obligation
is met as defined in the management service contract. Directors considering transaction price to be
clearly determined by amounts specified in the management service agreements. Directors considered
uncertainty of cash flows from sales to be limited, considering payments are made by companies with
excellent
track record of payments and clear definition of performance obligation upon which such
payment is made.

For breakdown of revenue from services recognised over time and at point of time, please refer to Note 6 to
Financial Statements.

2.20 Other income

to the
Tekcapital LLC was granted a loan from TD Bank,
Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March
27, 2020. The Group currently believes that its use of the loan proceeds will meet the conditions for forgiveness
of the loan, given similar loan was forgiven in 2020. In accordance with IAS 20, considering the forgiveness
criteria being met, the company recognized the grant in the income statement as revenue.

in the aggregate amount of $70,166 pursuant

The Group also recognised $90,928 from R&D relief under other income.

2.21 Interest income

Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective
interest rate applicable (10%).

3.1

Financial Risk Management

Financial risk factors

(a)

Portfolio Risk/Investment management

Investment into portfolio companies held by the Group requires long-term commitment with no certainty of
return.

The fair value of each portfolio company represents the best estimate at a point in time and may be
impaired if the business does not perform as well as expected, directly impacting the Group’s value and
profitability. This risk is mitigated as the size of the portfolio increases. The Group performed sensitivity
analysis with regards to assumptions used in determination of fair value of the portfolio in Note 12.

The Group also regularly monitors portfolio companies’ liquidity required for returns to occur.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

(b)

Credit Risk management

Credit risk is managed on a Group basis. In order to minimise this risk, the Group endeavours to only deal
with companies that are demonstrable creditworthy, and the Directors continuously monitor the exposure.
The Group’s maximum exposure to credit risk for the components of financial position at 30 November
2021 and 2020 is the carrying amount of its current trade and other receivables as illustrated in Note 15.

The Group monitors credit risk related to performance of portfolio companies, including considerations
related to recoverability of convertible loan notes issued. Progress is monitored and regular discussions
are held with management of portfolio companies to assess commercial progress and financial information
provided. The Group also monitors credit risk related to creditor amounts due from portfolio companies.

(c)

Liquidity Risk management

Cash flow forecasting is performed on a Group basis. The Directors monitor rolling forecasts of the Group’s
liquidity requirements to ensure it has sufficient cash to meet operational needs. At the reporting date the
Group held bank balances of US $3,550,917. All amounts shown in the consolidated statement of financial
position under current assets and current liabilities mature for payment within one year, with Trade and Other
Receivables exceeding Trade and Other Payables by US $28,620.

(d)

Financial risk management

The Company’s Directors review the financial risk of the Group. Due to the early stage of its operations the
Group has not entered into any form of financial instruments to assist in the management of risk during the
period under review.

(e)

Market risk management

Due to low value and number of financial transactions that involve foreign currency and the fact that the
Group has no borrowings to manage, the Directors have not entered into any arrangements, adopted or
approved the use of derivative financial instruments to assist in the management of the exposure of these
risks. It is their view that any exchange risks on such transactions are negligible.

The Group also regularly monitors risk related to fair value of financial instruments held such as convertible
loan notes held.

(f)

Foreign exchange risk management

Foreign exchange risk arises when individual Group entities enter into transactions denominated in a
currency other than their functional currency. The Group’s policy is, where possible, to allow Group entities to
settle liabilities denominated in their functional currency, with the cash generated from their own operations
in that currency. Where Group entities have liabilities denominated in a currency other than their functional
currency (and have insufficient reserves of that currency to settle them), cash already denominated in that
currency will, where possible, be transferred from elsewhere within the Group.

A sensitivity analysis has been performed to assess the exposure of
the Group to foreign exchange
movements. If the exchange rate weakened by 10 percent then the effect on the gain before tax would
decrease by US$2,523,579 and equity would decrease by US$6,477,104.

(g)

Impact of the COVID-19 pandemic

The current Coronavirus epidemic may produce negative economic activities which could reduce the
company’s economic performance and the performance of its portfolio companies in ways that are difficult to
quantify at this juncture. It may cause a recession in the markets in which the Group operates or significant
inflation, reduce the Group’s net asset values, revenue, cash flow, access to investment capital and other
factors which could negatively impact the Group.

(h)

Interest rate risk

The Group has no borrowings.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

3.2

Capital management

The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going
concern in order to provide returns for shareholders, benefits for other stakeholders and to maintain an
optimal capital structure to reduce the cost of capital.

In order to adjust or maintain the capital structure, the Group may adjust the level of dividends paid to its
to shareholders, issue new shares or sell assets to reduce borrowings. The
shareholders, return capital
Group has no external borrowings. This policy is periodically reviewed by the Directors, and the Group’s
strategy remains unchanged for the foreseeable future.

The capital structure of the Group consists of cash and bank balances and equity consisting of issued share
capital, reserves and retained losses of the Group. The Directors regularly review the capital structure of the
Company and consider the cost of capital and the associated risks with each class of capital. The Company
has no external borrowings.

The Company’s historic cost of capital has been the cost of securing equity financings, which have
averaged around 10%. The company’s long-term financial goal is to optimise its returns on invested capital
(ROIC) in excess of our weighted average cost of capital (WACC) and as such create value for our
shareholders. The method the Company seeks to employ for achieving this is to utilise its structural
intellectual capital developed through its Discovery Search Network, its Invention Evaluator service and its
Vortechs Group Service to mitigate selection bias and improve returns on invested capital. Ultimately,
management will seek to monetize these returns with exits from its investments in portfolio companies.

Critical accounting estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other
future events that are believed to be reasonable under the circumstances.
factors, including expectations of
The Directors made the following judgements:
- determination as to the classification of the Group as an investment entity as discussed in Note 2.4
- determination of operating segments as disclosed in Note 5
- determination of
discussed in Note 12.

the Group’s portfolio companies on funding to achieve their

reliance of

fair values

The Directors also make estimates and assumptions concerning the future. The resulting accounting
estimates will by definition, seldom equal the related actual results. The estimates and assumptions that have
a significant risk of causing a material adjustment to the carrying value of the assets and liabilities within the
next financial year are detailed below.

Potential
impact within
the next
financial
year

Potential
impact in
the longer
term

Note
reference
for
sensitivity
analysis

Yes

Note
12

Key estimate/
judgment area

Key assumption

Valuation of
unquoted
equity
investments

In applying valuation techniques to determine the fair value
of unquoted equity investments the Group and the
Company make estimates and assumptions regarding the
future potential of the investments. The policy of the Group
and the Company is to value new portfolio companies at
cost of the acquired IP or equity plus associated expenses
to facilitate the acquisition. Existing portfolio companies are
valued using either a market transaction such as third-party
funding or, in the absence of a recent market transaction, by
alternative methods and where appropriate by an external,
qualified valuation expert.
The fair value of Guident Limited reflects input in the form
of value of Guident Ltd’s shares in its US subsidiary
(Guident Corp) as determined by recent market transactions
of these shares.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

Key
estimate /
judgment
area

Key assumption

Potential
impact within
the next
financial year

Potential
impact in
the longer
term

Note
reference
for
sensitivity
analysis

This input was corroborated by Guident’s enterprise valuation
by estimating the net present value of
future cashflows
associated with its business. Key assumptions used in
estimating future cash flows are projected profits including
eyewear unit sales for company’s e-commerce channels as well
as number of retail stores to determine projected sales, and a
future
discount
cashflows from the platform.

factor applied for the net present value of

Valuation
of
unquoted
equity
investments

Deferred
Tax

transactions of

The fair value of Salarius Limited reflects input in the form of
value of Salarius Ltd’s shares in its US subsidiary (Microsalt
these
Inc) as determined by recent market
shares. This input was corroborated by Microsalt’s enterprise
valuation by estimating the net present value of
future
cashflows associated with its business. Key assumptions used
in estimating future cash flows are projected profits including
eyewear unit sales for company’s e-commerce channels as well
as number of retail stores to determine projected sales, and a
discount
future
cashflows from the platform.

factor applied for the net present value of

The fair value of Lucyd Limited reflects input in the form of
value of Lucyd Ltd’s shares in its US subsidiary (Innovative
Eyewear Inc) as determined by recent market transactions of
these shares. This input was corroborated by Innovative
Eyewear’s enterprise valuation by estimating the net present
future cashflows associated with its business. Key
value of
assumptions used in estimating future cash flows are projected
profits including eyewear unit sales for company’s e-commerce
retail stores to determine
channels as well as number of
projected sales, and a discount
the net
factor applied for
present value of future cashflows from the platform.

Deferred tax is the tax expected to be payable or recoverable on
differences between the carrying amounts of assets and
liabilities in the financial statements and the corresponding tax
bases used in the computation of taxable profit, and is
accounted for using the balance sheet liability method. Deferred
tax assets are recognised to the extent that it is probable that
taxable profits will be available against which deductible
temporary differences can be utilised. The carrying amount of
deferred tax assets is reviewed at each balance sheet date and
reduced to the extent that it is no longer probable that sufficient
taxable profits will be available to allow all or part of the asset to
be recovered. Deferred tax is calculated at the tax rates that are
expected to apply in the period when the liability is settled or the
asset is realised based on tax laws and rates that have been
enacted or substantively enacted at the balance sheet date. The
Group did not recognize deferred tax liability on fair value gains
associated with the revaluation of shares in its portfolio
companies due to availability of the substantial shareholdings
exemption. This is considered a permanent difference and not a
temporary difference.

Yes

Note 12

Yes

Note 21

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

Key
estimate/
judgment
area

Key assumption

Share based
payment

The estimate of share based payment requires the Director
to select an appropriate valuation model and make decisions
about various inputs into the model including the volatility of
its own share price, the probable life of options and the risk
free interest rate.

Segmental reporting

Potential
impact in
the longer
term

Note reference
for sensitivity
analysis

Potential
impact
within the
next
financial
year

Yes

Note 25

The Directors consider the business to have two segments for reporting purposes under IFRS 8 which are:
•

professional services, including the provision of recruitment services via Vortechs Group, provision of
invention evaluator services, as well as R&D tax relief credits and provision of management services to its
portfolio companies. The activities grouped under this segment share similar economic characteristics of
provision of intellectual property services to third party services;
licensing and investment activities,
including acquiring licences for technologies, portfolio company
investment, development and commercialisation. The activities share the goal of increasing the fair value
of investments made into portfolio companies by the Group.

•

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

6. Revenue from Services

The below table discloses disaggregated Revenue from Services by their nature/categories as well as
timing of the revenue. Please refer to Note 12 for disaggregation of Group’s Unrealised profit on the
revaluation of investments.

All of the Group’s major service lines are sold directly to consumers and not through intermediaries. All
revenue recognised in the reporting period represent performance obligations satisified in the current
period.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

6.1 Other Income

7. Operating expenses

7.1 Expenses by nature

7.2 Auditor remuneration

8. Employees

8.1 Director’s emoluments

The highest paid Director received a salary of US$191,825 (2020: $191,865) and benefits of US$24,098 (2020:
US$22,745). The highest paid Director received a bonus of US$191,825 (2020: US$154,375). The highest paid
Director did not exercise any share options. The share-based payments associated with the highest paid Director
amounted to US$28,117. No termination benefits, post-employment benefits were provided to Directors. Total of
short-term benefits in kind of US$22,745 were provided during the year. The amounts in the table above do not
include Employers NI in the amount of US$22,500.

Key management personnel (including Directors and Group Financial Controller) received salary of US$669,660,
excluding Stock Base Compensation disclosed in Directors Remuneration Report. Please also refer to Director’s
Report.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

8.2 Employee benefit expenses

8.3 Average number of people employed

Average number of employees with the Company in 2021 and 2020 was six, of which two were Management.
To enhance flexibility and improve cost control, the Group utilises consultants for scientific review, administrative and
operations support, software development and other knowledge-intensive services.

Income tax expense

The weighted average applicable tax rate was 19% (2020: 19%).

Unused tax losses for which no deferred tax assets have been recognised is attributable to the uncertainty
over the recoverability of those losses through future profits.

Future UK corporate income tax rate of 25% will be applicable for the financial year beginning 1 December
2023.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

10. Earnings per share

Basic earnings per share is calculated by dividing the earnings attributable to ordinary shareholders by the
weighted average number of Ordinary Shares outstanding during the period.

Diluted earnings per share is calculated by dividing the earnings attributable to ordinary shareholders by the
sum of weighted average number of (1) Ordinary Shares outstanding during the period and (2) any dilutive
potential Ordinary Shares outstanding at 30 November 2021:

The Group completed placements of total of 48,714,286 new ordinary shares during the financial year.

11. Investments in subsidiaries

During the year the directors determined a provision for impairment was required for Company’s investments in
Tekcapital LLC.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

As at the year end, the Group has no interest in the ownership of any other entities or exerts any significant
influence over or provides funding which constitutes an “unconsolidated structured entity”.
All UK subsidiaries are exempt from the requirement to file audited accounts by virtue of section 479A of the
Companies Act 2006.
Tekcapital Europe Ltd (registered address 12 New Fetter Lane, London, United Kingdom, EC4A 1JP) and
Tekcapital LLC (registered address 11900 Biscayne Blvd, Suite 630, Miami, Florida, 33181, United States)
are consolidated by Tekcapital plc because they continue to provide advisory services in IP search and
technology transfer.
All other entities are measured at fair value through profit and loss based in IFRS 10 as referenced in Note
2.4. The Group provides management service support
to Lucyd Limited, Salarius Limited and Guident
Limited, as well as has provided working capital assistance to Salarius Limited and Guident Limited through
convertible loan note financing (see also Note 15). The Group also assists the entities with their fundraising
activities.
Registered office of all four subsidiaries owned by Tekcapital Europe Limited: Acre House, 11-15 William
Road, London, England, NW1 3ER.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

12. Financial Assets at Fair Value through Profit and Loss

The Group’s financial assets at fair value through profit and loss consist of equity investments (2021:US
$62,523,638, 2020:US $ 30,491,657) and convertible loan notes (2021:US$1,341,774, 2020:US $588,169)
totalling US $63,865,432 (2020:US $31,079,826).

12.1 Equity Investments

The Group’s investments in portfolio companies in the years ended 30 November 2021 and 30 November
2020 are listed below. The principal place of business for portfolio companies listed below is the UK and in
the U.S..

Total fair value gain of US $28.1m for the year reflects uplift in value of shares of Belluscura, Lucyd and
Salarius, offset partially by reduction in fair value of Guident. Considering early stage of commercialisation, fair
value of Smart Food Tek was recorded based on the cost of acquired IP, as their carrying amounts represent a
reasonable approximation of fair value.
The valuation techniques used fall under, Level 2 – Observable inputs, such as quoted price in an active
market, and Level 3- Other techniques as defined by IFRS 13. These techniques were deemed to be the best
evidence of fair values considering early stage of portfolio companies.

Fair value measurement hierarchy for financial assets as at 30 November 2021 with comparative amounts as of
30 November 2020:

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

Transfer of investment in Belluscura from Level 2 to Level 1 occurred during the period as the company’s
shares commenced trading on AIM market of London Stock Exchange, providing quoted prices (unadjusted) in
active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date.

Belluscura (US $18.8m gain)
The fair value of the holding increased by US$18.8m during the year due to Company’s listing at AIM market of
London Stock Exchange, and closing price of 94p as of 30 November 2021. With 17,138,767 shares held by
Tekcapital plc, a fair value of $22,695,518 was arrived at as of 30 November 2021.

Lucyd (US $12.5m gain)
The fair value of the holding increased by US$12.5m during the year as a result of:

Valuation of 4,922,115 shares held in Innovative Eyewear, as determined by the price paid by investors in
•
the most recent Regulation Crowdfund offering ($3.56 per share, or $20m pre money valuation), at
$17,522,729
•

Net book value of other assets and liabilities of ($177,534).

In July 2021, the Company launched its second Crowdfunded offering of common stock in which it raised
$149,480, amounting to 45,355 shares. Innovative Eyewear received funding using REG CF crowdfunding that
allows the companies to sell stock to third-party, arms-length, independent investors. As such, valuing Lucyd
Ltd’s ownership in Innovative Eyewear based on the share price paid by REG CF investors appears to fall within
company’s policy of valuing its investments based on recent third-party funding.

This input was corroborated by Innovative Eyewear’s enterprise valuation by estimating the net present
value of future cashflows associated with its business.. Key assumptions used in estimating future cash
flows are:
-

projected profits of $46.7m through 2026 including eyewear unit sales for company’s e-commerce
channels

- Corporate income tax rate of 21% applied to net profit of $46.7m
-

13% discount rate used to discount proceeds as determined by opportunity cost (6%), inflation rate (5%)
and technology risk (2%).

The management believes the valuation using discounted cash flow method as of 30 November 2021 of
$23.1m approximates the REG CF observed valuation of $20m, therefore $3.56 per shares is reasonable fair
value estimate of its shares in Innovative Eyewear Inc.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

Adjusted for Net Book Value of ($177,534) of other assets and liabilities held by Lucyd Ltd as of 30
November 2021, the fair value of Lucyd Ltd shares held by Tekcapital Europe was estimated at
$17,345,195, compared to $2,699,331 as of 30 November 2020.

Salarius (US $0.7m gain)
The fair value of the holding increased by US$0.7m during the year as a result of:

Valuation of 4,356,521 shares held in Microsalt Inc, as determined by the price paid by investors in
•
the most recent Regulation Crowdfund offering ($1 per share, or $5m pre money valuation), at
$4,356,520.

In December 2020, the Company launched its second Crowdfunded offering of common stock in which it
raised $749,978, amounting to 749,978 shares. Microsalt
Inc received funding using REG CF
crowdfunding that allows the companies to sell stock to third-party, arms-length, independent investors.
As such, valuing Salarius Ltd’s ownership in Innovative Eyewear based on the share price paid by REG CF
investors appears to fall within company’s policy of valuing its investments based on recent third-party
funding.

This input was corroborated by Microsalt’s enterprise valuation by estimating the net present value of
future cashflows associated with its business.. Key assumptions used in estimating future cash flows
are:
-
- Corporate income tax rate of 21% applied to net profit of $12.9m
-

13% discount rate used to discount proceeds as determined by opportunity cost (6%), inflation rate
(5%) and technology risk (2%) .

projected profits of $12.9m through 2026 including sales of Microsalt® and SaltMe® crisps.

The management of Salarius Ltd believes the valuation using discounted cash flow method as of 30
November 2021 of $6.1m approximates the REG CF observed valuation of $20m, therefore $1 per
shares is reasonable fair value estimate of its shares in Microsalt Inc.

Adjusted for Net Book Value of ($0) of other assets and liabilities held by Salarius Ltd as of 30
November 2021, the fair value of Salarius Ltd shares held by Tekcapital Europe was estimated at
$4,356,521, compared to $3,638,304 as of 30 November 2020.

Guident Ltd (US $3.9m loss)
The fair value of the holding decreased by US$3.9m during the year as a result of:

Net Book Value of Guident Ltd of $18,083,264 as of 30 November 2021 consists of Valuation of
•
18,115,942 shares held in Guident CORP, as determined by the price agreed between Guident CORP and
by investors in the most recent Private Placement Memorandum offering at $1 per share.

In August 2021, Guident CORP entered into Private Placement Memorandum outlining offering of
securities at $1 per unit, with each unit consisting of one share of Class A Convertible Preferred Stock
and a Warrant to acquire a share of common stock (also at $1 per unit). While Guident has not
received funding from the offering until after the reporting date, the management considers the exit
price (of securities offered in the private placement) negotiated with the investment bank as “privately
IFRS 13. The Offering has
negotiated acquisition of
facilitated by Dawson James Securities Inc. Dawson James is a broker-dealer registered with the SEC
as a broker dealer and is a member of FINRA. FINRA is currently the only such registered national
securities association in the U.S.

the equity instruments” as defined under

This input was corroborated by Guident CORP’s enterprise valuation by estimating the net present
value of future cashflows associated with its business. Key assumptions used in estimating future cash
flows are:

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

projected profits of $41m through 2026 including teleoperation software sales across ground delivery
devices, transportation services and commercial fleets.

- Corporate income tax rate of 21% applied to net profit of $41m
-

13% discount rate used to discount proceeds as determined by opportunity cost (5%), inflation rate (5%) and
technology risk (3%) .

The enterprise valuation calculated using Discounted Cash Flow method as of 30 November 2021 was $20m.
The management believes the valuation using discounted cash flow method as of 30 November 2021 of $20m
approximates the negotiated valuation of US$24m, therefore $1 per shares is reasonable fair value estimate of
its shares in Guident Corp.

Smart Food Tek (Nil Gain / Nil loss)
Considering early commercialisation stage, the Group records its investment in Smart Food Tek at cost. The
directors do not consider that any other available information would materially change or give a more reliable
representation of the value.

The Group exercised judgment in determination of sufficiency of portfolio companies’ cash reserves, forecasts
and ability to raise money to achieve their fair values. Directors reviewed and questioned the forecasts used,
standing liquidity and working capital balances, as well as discussed capability and plans to raise money in the
future with directors or management of portfolio companies. Based on the review, the Group made a positive
determination as to portfolio companies’ likely ability to achieve fair values considering liquidity factors.

The significant unobservable inputs used in the fair value measurement categorised within Level 3 of the fair
value hierarchy, together with a quantitative sensitivity analysis as at 30 November 2021 are shown as below.
No sensitivities have been included on the other investments not listed in the table below as their fair value
equates to cost.

N O T E S T O T H E FI NANCI AL S T AT E M E N T S

12.2 Convertible loan notes

The Group also held multiple convertible loans issued by its portfolio companies, including:

• Convertible note issued by Innovative Eyewear Inc, for the total of US$2,000,000 that bears interest at 10%
per annum, which includes the option to convert the debt into the Company's common stock at market price.
The note can be converted into shares of common stock of the Company upon occurrence of certain
conversion events, as defined.

On June 1, 2021, Innovative Eyewear converted related party borrowings totaling $778,500 into 778,500
shares of common stock at $1 each.

On September 5, 2021, Innovative Eyewear converted related party borrowings totaling $500,002 into
140,449 shares of common stock at $3.56 each.

On November 1, 2021, Innovative Eyewear executed an addendum for its December 1, 2020, convertible
note
agreement with Parent and Affiliates, increasing the amount of available financing from $2,000,000
to $3,000,000.

On November 16, 2021, Innovative Eyewear converted related party borrowings totaling $901,271 into
253,166 shares of common stock at $3.56 per share.

Consequently, the Company presented the amount of US$2,179,773 under additions to “Financial Assets
Held at Fair Value” as at 30 November 2021 (see Note 12). As of 30 November 2021, US$3,643 was
outstanding as the convertible note receivable.

• Convertible note issued by Guident Ltd for the total of US$1,000,000, issued at 10% coupon rate including
option to convert the debt into shares at market price (no discount against future equity placements offered).
The note can be converted into Guident’s equity upon occurrence of certain conversion events. The
US$1,000,000 note originated in March 2020 or can be converted into Guident’s equity upon occurrence of
certain conversion events. US$1,088,131 was drawn as at 30 November 2021. No conversions occurred
during the period. As of 30 November 2021, US$660,413 was
note
receivable.

outstanding

convertible

the

• Convertible note issued by its portfolio company, Microsalt Inc, for the total of US$250,000, issued at 10%
coupon rate including option to convert the debt into shares at market price (no discount against future equity
placements offered). The note can be converted into Microsalt’s equity upon occurrence of certain conversion
events. The US$ 250,000 note originated in September 2020 is payable in September 2023 or can be
converted into Microsalt’s equity upon occurrence of certain conversion events. US$677,718 was drawn and
outstanding as of 30 November 2021. No conversions occurred during the period.

The Group has previously recognised convertible note loan balances at cost under non-current assets. The
accounting policy has been updated from the prior year to measure the balances at fair value. The resulting
adjustment was not material to Group’s financial statements.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

13. Intangible assets

The Directors have undertaken an impairment review based on the future cash flow projections of the Vortechs Group
intangible asset and consider the recoverable amount to be $37,229 lower than the carrying value and have therefore
recorded an impairment.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

14. Property, plant and equipment

15. Trade and other receivables

The fair value of trade and other receivables are not materially different to those disclosed above. The Group’s
exposure to credit risk related to trade receivables is detailed in Note 3 to the consolidated financial statements.

The Group had outstanding receivables from its portfolio companies as at 30 November 2021 in the amount of:

- US$85,391 due from Lucyd Ltd
- US$104,912 due from Smart Food Tek Ltd
- US$392,252 due from Guident Ltd.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

16. Cash and cashequivalents

17. Categories of financial assets and financialliabilities

18. Share capital

The shares have full voting, dividend and capital distribution (including on winding up) rights; they do not
confer any rights of redemption. The following shares were issued during the year:
• March 2021: 38,000,000 shares were issued in the placing of new ordinary shares at £0.10p. Total
proceeds of US$5,432,322 were netted against cost of raising finance in the amount of US$301,253
• November 2021: 10,714,286 shares were issued in the placing of new ordinary shares at £0.28p. Total
proceeds of US$4,274,564 were netted against cost of raising finance in the amount of US$261,040

The Company has authorised share capital of 141,592,328, with a nominal value of £0.004. Of these shares,
141,549,328 were issued and fully paid up.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

19. Trade and other payables

The fair values of trade and other payables are not materially different to those disclosed above.

The Group’s exposure to currency and liquidity risk related to trade and other payables is detailed in note 3 to
the accounts.

20. Deferred Revenue

The Group’s deferred revenue balance of US$154,721 as of 30 November 2020 was adjusted for:
•

receipt of Invention Evaluator payments in the amount of US$37,854 to be delivered after 30 November
2021, recognized as addition to the balance deferred revenue during the year ended 30 November 2021
recognition of US$23,292 of revenue deferred as of 30 November 2020 for reports delivered during the
financial year 2021 bringing the total outstanding balance of Deferred Revenue as at 30 November 2021
to US$169,287.

•

21. Deferred income tax

Unused tax losses for which no deferred tax assets have been recognised is attributable to the uncertainty
over the recoverability of those losses through future profits. A tax rate of 19% has been used to calculate
the potential deferred tax.

22. Dividends

No dividend has been recommended for the year ended 30 November 2021 (2020: Nil) and no dividend was
paid during the year (2020: Nil).

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

23. Cash used from operations

24. Commitments

Capital commitments
The Group entered into multiple convertible loan note agreements with its portfolio companies. Please see note
15 for details regarding outstanding commitments.

Lease commitments
The Group did not have any material contracts withing the scope of IFRS 16. Consequently, the Group did not
recognise any right-of-use assets and lease liabilities during the period.

25. Share based payments

The Group operates an approved Enterprise management scheme and an unapproved share option
scheme.

The fair value of the equity settled options granted is expensed over the vesting period and is arrived at
using the Black-Scholes model. The assumptions inherent in the use of this model are as follows:

The weighted average fair value of options outstanding was £0.03p. Volatility was calculated using Group’s
historical share price performance since 2017. The share-based payment expense for the year was
$111,145 (2020: $44,273). Details of the number of share options and the weighted average exercise price
outstanding during the year as follows:

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

*The weighted average exercise price for the options exercisable as at 30 November 2021 and 30 November
2020 was £0.19p and £0.19p respectively.

The weighted average remaining contractual
life is 2.9 years (2020: 4.2 years). The weighted average fair
value of options granted during the year was £0.03p (2020: £0.03p). The range of exercise prices for options
outstanding at the end of the year was £0.052p - £0.31p (2020: £0.065p - £0.46p).

26. Related party transactions

Details of Directors’ remuneration and grant of options are given in the Directors’ report. Please also refer
to Note 8.1 for payments related to key management personnel.

525,000 options were held by Harrison Gross, family member of Dr. Clifford Gross (2020: 525,000).

Please refer to tables below for detail of relationships and transactions between The Group and its
subsidiaries.

N O TE S T O T H E FI NANCI AL S TA TEM E N TS

Related party transactions were made on terms equivalent
transactions are made only if such terms can be substantiated.

to those that prevail

in arm’s length

27. Events after the reporting period

Post period end, following amounts were drawn for existing convertible notes:
• US$628,405 for Microsalt Inc
• US$262,546 for Guident CORP
• US1,431,068 for Innovative Eyewear Inc

The senseless Russian invasion of Ukraine has not had a material impact on our business to-date, as far as
we can discern at this early juncture, as we do not have direct business exposure to either Russia or the
Ukraine. However, over time the conflict may contribute to inflation of energy costs and supply chain disruption
which could increase the cost and complexity of souring components for some of our portfolio companies.

C O M P A N Y STA TEM ENT O F FI NANCIAL P O SI TI ON AT 3 0
NOVEM BER 2021

The Company’s profit after tax for the year ended 30 November 2021 was US$16,604,995 (loss after
tax for the year ended 2020: US$316,239).

The Company has used the exemption under S408 CA 2006 not to disclose the Company income as
primary statement.

The notes on pages 80 to 83 are an integral part of these financial statements.

The financial statements on pages 78 to 83 were approved and authorised for issue by the Board of
Directors on 5 May 2022 and were signed on its behalf.

Louis Castro
Director

Tekcapital PLC
registered number
08873361

Dr Clifford M Gross
Chairman and CEO

CO M P A N Y STATEM ENT O F C H A N G E S IN TH E EQUI TY F O R
TH E Y E A R EN DED 3 0 NOVEM BER 2021

Share premium – amount subscribed for share capital in excess of nominal value, net of directly attributable
issue costs.

Translation reserve – foreign exchange differences recognized in other comprehensive income.

Retained earnings – cumulative net gains and losses recognized in the consolidated financial statements of
comprehensive income

The notes on pages 80 to 83 are an integral part of these financial statements.

N O TE S T O T H E C O M P A N Y FI NANCI AL S TA TEM E N TS

C.1.

General Information

Tekcapital PLC (Companies House registration number: 08873361) is a company incorporated in England
and Wales and domiciled in the UK. The address of the registered office is detailed on page 28 of these
financial statements. The Company is a public limited company limited by shares, which listed on the AIM
market of the London Stock Exchange in 2014. The principal activity of the company is that of investment
in portfolio companies. The Company also acquires exclusive licences to university technologies that it
believes can positively impact people’s lives, for subsequent commercialisation.

The Company had no employees during the period.

C.2

Statement of Compliance

The financial statements of
the parent company have been prepared in accordance with Financial
Reporting Standard 101 “Reduced disclosure framework” (‘FRS 101’). The company will continue to
prepare its financial statements in accordance with FRS101 on an ongoing basis until such time as it
notifies shareholders of any change to its chosen accounting framework.

The principal accounting policies applied in the preparation of these financial statements are set out in
Note 2 of the consolidated financial statements.

Exemptions
The Company financial statements have been prepared using the historical cost convention except
where other measurement basis are required to be applied and in accordance with IFRS under FRS 101.
In accordance with FRS101, the company has taken advantage of

the following exemptions:

•
•
•
•
•
•

Statement of Cash Flows
Financial instrument disclosures.
Capital management disclosures.
Additional comparative information.
A reconciliation of share options in the year
Related party disclosures with wholly owned subsidiaries

Changes in accounting policy and disclosures

All changes to accounting standards are explained in note 2 to the consolidated financial statements.

C.3

Profit/(loss) for the year

As permitted by section 408 of the Companies Act 2006, the Company has elected not to present its own
profit and loss account for the year. The auditor’s remuneration for audit and other services is disclosed
in note 7 to the consolidated financial statements.

C.4

Investment in subsidiaries.

Investments in subsidiaries are stated at cost less any adjustment for impairment. The Company recorded
US$1,103,550 in impairment charge related to its investment in Tekcapital LLC.

N O TE S T O T H E C O M P A N Y FI NANCI AL S TA TEM E N TS

* As at the year end, the Company has no interest in the ownership of any other entities or exerts any
significant influence over or provides funding which constitutes an “unconsolidated structured entity”.
All UK subsidiaries are exempt from the requirement to file audited accounts by virtue of section 479A of
the Companies Act 2006.
Tekcapital Europe Ltd (registered address 12 New Fetter Lane, London, United Kingdom, EC4A 1JP)
and Tekcapital LLC (registered address 11900 Biscayne Blvd, Suite 630, Miami, Florida, 33181, United
States) are consolidated by Tekcapital plc because they continue to provide advisory services in IP
search and technology transfer.

C.5 Financial Assets at Fair Value through Profit and Loss

Company’s investment in Belluscura plc in the years ended 30 November 2021 and 30 November 2020 is
listed below and classified as equity instruments. The principal place of business for Belluscura plc is
England and Wales.

The valuation technique used falls under, Level 2 – Observable techniques, other than quoted prices.

The fair value of the holding increased by US$19.4m during the year due to Company’s listing at AIM market of
London Stock Exchange, and closing price of 94p as of 30 November 2021. With 17,138,767 shares held by
Tekcapital plc, a fair value of $22,695,519 was arrived at as of 30 November 2021.

C.6 Trade and other receivables

N O TE S T O T H E C O M P A N Y FI NANCI AL S TA TEM E N TS

The Company recorded a historical US$2,500,000 provision against its receivable from one its subsidiaries,
Tekcapital LLC. The remaining receivable due from Tekcapital LLC will be recovered in greater than one year.

C.7 Cash and cash equivalents

C.8 Categories of financial assets and financial liabilities

C.9 Share capital

N O TE S T O T H E C O M P A N Y FI NANCI AL S TA TEM E N TS

The Company has authorised share capital of 141,592,328, with a nominal value of £0.004. Of these shares,
141,592,328 were issued and fully paid up.

C.10 Trade and other payables

C.11 Deferred income tax

C.12 Dividends

No dividend has been recommended for the year ended 30 November 2021 (2020: Nil) and no dividend was
paid during the year (2020: Nil).

S TA Y I N TO U C H

U.K: +44 (0) 1865 338102

U.S: +1 (305) 200-3450

12 New Fetter Lane

London, EC4A 1JP

United Kingdom

E-mail: info@tekcapital.com